<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006592</article-id><article-id pub-id-type="pmc">PMC11859595</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020225</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00225</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Drug Delivery Systems Based on Metal&#x02013;Organic Frameworks for Tumor Immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Ning</given-names></name></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Zongyan</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-0136-3132</contrib-id><name><surname>Lang</surname><given-names>Tianqun</given-names></name><xref rid="c1-pharmaceutics-17-00225" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>D&#x000fc;zg&#x000fc;ne&#x0015f;</surname><given-names>Nejat</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00225">Lin Gang Laboratory, Shanghai 200031, China; <email>yangning@lglab.ac.cn</email> (N.Y.); <email>hezongyan0379@lglab.ac.cn</email> (Z.H.)</aff><author-notes><corresp id="c1-pharmaceutics-17-00225"><label>*</label>Correspondence: <email>langtq@lglab.ac.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>225</elocation-id><history><date date-type="received"><day>08</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>01</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>07</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Metal&#x02013;organic frameworks (MOFs) are a class of inorganic-organic hybrid nanoparticles formed by the coordination of metal ions/clusters and organic ligands. Due to their high porosities, large surface areas, adjustable structures, and responsiveness to light/sound, etc., MOFs have shown great clinical potential in the field of tumor therapy. Tumor immunotherapy exerts antitumor effects through reshaping tumor immune microenvironment, showing significant preclinical and clinical advantages. Based on the mechanisms of immunity activation, the tumor immunotherapy agents can be divided into chemotherapeutic agents, immunomodulators, enzymes, tumor vaccines and oligonucleotide drugs, etc. Herein, we review the MOFs-based drug delivery systems for tumor immunotherapy. The classification of MOFs, followed by their antitumor immunity activation mechanisms, are first introduced. Drug delivery systems based on MOFs with different immunotherapy agents are also summarized, especially the synergetic immunity activation mechanisms triggered by MOFs and their loadings. Furthermore, the merits and drawbacks of MOFs and the potential strategies for MOFs to promote their clinical applications are discussed.</p></abstract><kwd-group><kwd>MOFs</kwd><kwd>tumor immunotherapy</kwd><kwd>drug delivery</kwd></kwd-group><funding-group><award-group><funding-source>Shanghai Post-doctoral Excellence Program</funding-source><award-id>2023017</award-id></award-group><award-group><funding-source>&#x0201c;Science and Technology Innovation Action Plan&#x0201d; Sailing Plan of Shanghai</funding-source><award-id>22YF1460500</award-id></award-group><funding-statement>Please add: Shanghai Post-doctoral Excellence Program (2023017), and &#x0201c;Science and Technology Innovation Action Plan&#x0201d; Sailing Plan of Shanghai (22YF1460500) are gratefully acknowledged for financial supports.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00225"><title>1. Introduction</title><p>Cancer accounted for nearly 10 million deaths&#x02014;approximately one-sixth of the total&#x02014;in 2020, making it a leading cause of death [<xref rid="B1-pharmaceutics-17-00225" ref-type="bibr">1</xref>]. Tumor immunotherapy exerts antitumor effects by reshaping the tumor immune microenvironment (TIME) to elicit antitumor immune responses and surmounting immune evasion, which has led to a paradigm shift in the treatment of cancers [<xref rid="B2-pharmaceutics-17-00225" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-00225" ref-type="bibr">3</xref>]. Several immunotherapeutic agents have been used in the clinical management of cancers, conferring significant clinical advantages [<xref rid="B4-pharmaceutics-17-00225" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-17-00225" ref-type="bibr">5</xref>].</p><p>The tumor microenvironment (TME) is a complex ecosystem, encompassing tumor cells, stromal cells, immune cells, tumor blood vessels, etc. [<xref rid="B6-pharmaceutics-17-00225" ref-type="bibr">6</xref>]. These jointly foster a hypoxic, acidic, and nutrient-deficient microenvironment that contributes to an immunosuppressive phenomenon known as the &#x0201c;cold&#x0201d; tumor [<xref rid="B7-pharmaceutics-17-00225" ref-type="bibr">7</xref>]. Immunotherapeutic drugs activate the tumor immunological microenvironment and transform &#x0201c;cold&#x0201d; tumors into &#x0201c;hot&#x0201d; ones, which can be divided as follows: (1) chemotherapeutic agents with immunogenic cell death (ICD) effects; (2) immunomodulators; (3) enzymes; (4) tumor vaccines; and (5) oligonucleotide drugs, among others.</p><p>Despite different mechanisms, these agents ultimately lead to initiate antitumor immunity through the following steps: (1) the release of cancer cell antigens to trigger the immune response; (2) the recruitment of antigen-presenting cells (APCs), such as macrophages and dendritic cells (DCs); (3) the facilitation of macrophage polarization and DC maturation; (4) migration of DCs to tumor-draining lymph nodes (TDLNs); (5) the infiltration of cytotoxic T cells (CTLs); and (6) the elimination of tumor cells by CTLs (<xref rid="pharmaceutics-17-00225-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B8-pharmaceutics-17-00225" ref-type="bibr">8</xref>]. Nonetheless, under the regulation of various mechanisms, such as diminished antigen presentation, secretion of immunosuppressive factors, recruitment of immunosuppressive cell populations, upregulation of negative regulatory pathways, etc., tumor immunotherapy still faces numerous challenges [<xref rid="B9-pharmaceutics-17-00225" ref-type="bibr">9</xref>]. In addition, tumor cells evade immunologic surveillance through diverse drug resistance mechanisms, including primary, adaptive, and acquired resistance, thus limiting the effectiveness of immunotherapy [<xref rid="B10-pharmaceutics-17-00225" ref-type="bibr">10</xref>]. The judicious design and functional development of delivery systems hold promise as a potent method to improve the effects of tumor immunotherapy.</p><p>The stable and highly targeted drug delivery systems utilizing nanotechnology improve the effects of cancer immunotherapy. Metal&#x02013;organic frameworks (MOFs) were first proposed in 1995 [<xref rid="B11-pharmaceutics-17-00225" ref-type="bibr">11</xref>], which referred to a class of inorganic-organic hybrid nanoparticles formed by the coordination of metal ions/clusters and organic ligands. Typically characterized by regular polygonal rigid structures and high porosity, MOFs exhibit flexible and adjustable structures, making them burgeoning candidates as drug delivery carriers [<xref rid="B12-pharmaceutics-17-00225" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-00225" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-00225" ref-type="bibr">14</xref>]. MOFs have the following advantages: (1) the high porosity and large surface area provide ample space for drug encapsulation, thereby improving the drug-loading capacity; (2) the wide variety of organic ligands endows MOFs with designed multifunctionality, as many ligands can serve as functional sites for specific molecular recognition; (3) the structure of MOFs can be flexibly adjusted to cater to different active ingredients; (4) the surface of MOFs can be modified for improved biocompatibility, biodegradability and the capability of responsive drug release. First used in biomedical imaging research in 2006 [<xref rid="B15-pharmaceutics-17-00225" ref-type="bibr">15</xref>], MOFs have shown great clinical potential in the field of tumor therapy, with NCT 03444714 marking MOFs to enter clinical trials as a radiosensitizer for tumors [<xref rid="B16-pharmaceutics-17-00225" ref-type="bibr">16</xref>]. Studies employing MOFs as delivery carriers for tumor immunotherapy are emerging, providing important references for MOFs in clinical cancer immunotherapy transformation.</p><p>Recent studies have shown that the delivery of tumor immunotherapy drugs by MOFs can elicit a synergistic activation of tumor immunity through multiple pathways, thus improving the therapeutic effects. Herein, we summarized the relevant studies, most of which are within the last five years, on tumor immunotherapy using MOFs-based delivery systems, encompassing studies on the tumor immunostimulatory effects and mechanism of MOFs alone and MOFs as a delivery carrier of chemotherapy drugs, immunomodulators, tumor vaccines, and oligonucleotide drugs (<xref rid="pharmaceutics-17-00225-f002" ref-type="fig">Figure 2</xref>). In this review, immunotherapeutic agents encapsulated within MOFs were employed as the classification criteria, offering an innovative perspective of MOFs. This provided a new viewpoint and facilitated researchers to quickly navigating their interested domain. After that, we discussed the prospects of MOFs in tumor immunotherapy.</p></sec><sec id="sec2-pharmaceutics-17-00225"><title>2. Classification and Drug Loading of MOFs</title><p>The synthesis of MOFs is based on the coordination bond between metal ions/clusters and organic ligands, therefore combining the merits of organic substances and inorganic molecules. Owing to the extensive variety of metal ions/clusters and organic ligands, the structures of MOFs are theoretically infinite [<xref rid="B17-pharmaceutics-17-00225" ref-type="bibr">17</xref>]. To date, over 80,000 types of MOFs have been designed and synthesized, showcasing a wide application prospect. According to the kind amount of metal ions/clusters, MOFs can be categorized into single-metal MOFs, binary-metal MOFs, and multi-metal MOFs. Based on the type of metal ions/clusters, prominent research focus includes the ZIF-8 based on zinc (Zn) and imidazole ligands, MIL-100 synthesized by iron (Fe) and carboxylate ligands, and UiO-66 formed by zirconium (Zr) and terephthalic acid ligands, etc. Dimensionally, MOFs can be classified into one-dimensional rod-shaped MOFs (1-D MOF rods), two-dimensional sheet-like MOFs (2-D MOF sheets), and three-dimensional nanoparticles MOFs (3-D MOF NPs) (<xref rid="pharmaceutics-17-00225-f003" ref-type="fig">Figure 3</xref>a). The synthetic methods for MOFs include self-assembly, solvothermal, electrochemical, mechanical grinding, microwave, ultrasonic techniques, etc. [<xref rid="B18-pharmaceutics-17-00225" ref-type="bibr">18</xref>]. The solvothermal method, which operates under high temperature and pressure conditions, yields MOFs of enhanced uniformity. Microwave synthesis is rapid and efficient, and self-assembly methods with its mild conditions and ease of operation have emerged as a preferred technique in recent years.</p><p>MOFs exhibit profound advantages as drug carriers. During the synthesis of MOFs, the metal ions/clusters as centers are interconnected via coordination and covalent bonds, constructing a framework that boasts a remarkably high specific surface area and a porosity of up to 90% [<xref rid="B17-pharmaceutics-17-00225" ref-type="bibr">17</xref>], thereby providing an enormous space for drug loading. For example, the MIL-100 and MIL-101 MOFs constructed by Horcajada et al. accommodated ibuprofen at a loading capacity of up to 60% [<xref rid="B19-pharmaceutics-17-00225" ref-type="bibr">19</xref>]. The surface of MOFs can be modified to adjust their properties, such as enhancing stability, endowing targeting ability, altering surface charge, improving water solubility, and reducing cytotoxicity, thus further improving the performance of MOFs as drug carriers. For example, the chemical and colloidal stabilities of MIL-100 NPs were improved with polyethylene glycol (PEG) surface modification [<xref rid="B20-pharmaceutics-17-00225" ref-type="bibr">20</xref>], and ZIF-8 NPs were endowed with tumor targeting ability with methoxy-PEG-folate (PEG-FA) coating [<xref rid="B21-pharmaceutics-17-00225" ref-type="bibr">21</xref>]. Another instance involved modifying the surface of MOFs with hyaluronic acid (HA) to endow them with responsiveness to hyaluronidase in the TME [<xref rid="B22-pharmaceutics-17-00225" ref-type="bibr">22</xref>]. Moreover, due to the presence of metal ions, MOFs are responsive to stimuli such as sound, light, magnetic fields, and pH, and this feature can be further enhanced by incorporating materials like sonosensitizers and photosensitizers. The advantages of MOFs as drug carriers have made them shine in antitumor therapy and also possess great potential in tumor immunotherapy.</p><p>MOFs can achieve drug-loading through several methodologies (<xref rid="pharmaceutics-17-00225-f003" ref-type="fig">Figure 3</xref>b). These are as follows. (1) Immersion: the drug molecules enter the pores of MOFs or adhere to their surfaces through host&#x02013;guest interactions or electrostatic adsorption by simply blending a drug solution with MOFs [<xref rid="B23-pharmaceutics-17-00225" ref-type="bibr">23</xref>]. (2) Co-crystallization, also known as the &#x0201c;one-pot method: the drug molecules are directly added into the synthetic solution containing metal ions and organic ligands during the synthesis of MOFs, where the drug co-crystallizes with MOFs, forming the MOF skeletons with the drug molecules inside [<xref rid="B24-pharmaceutics-17-00225" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00225" ref-type="bibr">25</xref>]. (3) Drug as organic ligands: the drug molecules can work as organic ligands to form MOFs [<xref rid="B26-pharmaceutics-17-00225" ref-type="bibr">26</xref>], and this method obviates the addition of organic ligands and significantly improves the drug-loading capacity.</p><p>In the meantime, the problems MOFs are facing as drug carriers should not be ignored. Among these issues, toxicity and biocompatibility are the first two to be solved. The toxicity of MOFs is deeply dependent on the concentration [<xref rid="B27-pharmaceutics-17-00225" ref-type="bibr">27</xref>], and both the metal and organic linkers have effects on it. For example, MOFs containing Fe show less cytotoxicity than those containing Zr or Zn [<xref rid="B28-pharmaceutics-17-00225" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00225" ref-type="bibr">29</xref>]. Furthermore, the hydrophobic&#x02013;hydrophilic balance is the main factor to influence the toxicity of MOFs, since it has a direct effects on the removal speed of the nanoparticles. Moreover, the cellular uptake speed of MOFs is related to their cytotoxicity [<xref rid="B28-pharmaceutics-17-00225" ref-type="bibr">28</xref>]. To better improve their biocompatibility and reduce their toxicity, surface modification is generally employed on MOFs. PEG [<xref rid="B20-pharmaceutics-17-00225" ref-type="bibr">20</xref>], folic acid [<xref rid="B30-pharmaceutics-17-00225" ref-type="bibr">30</xref>], and hyaluronic acid [<xref rid="B31-pharmaceutics-17-00225" ref-type="bibr">31</xref>] are common surface modifications for MOFs, which also have surface functionalization effects. Another important concern comes to their stability, which has a deep impact on the distribution, biodegradability and metabolism in vivo. Most MOFs are stable to heat, since they can be synthesized under high temperature conditions. Zn-based MOFs are easily degraded under acidic conditions, endowing them with the TME responsive characteristics [<xref rid="B21-pharmaceutics-17-00225" ref-type="bibr">21</xref>]. MOFs of MIL family degrade quickly in PBS or cell culture media due to the presence of phosphate ions, while NU-1000 degraded slowly under high concentrations of them [<xref rid="B32-pharmaceutics-17-00225" ref-type="bibr">32</xref>]. As relative new carriers for drugs, there are limited studies on MOFs&#x02019; release dynamics and metabolism, especially in vivo ones [<xref rid="B33-pharmaceutics-17-00225" ref-type="bibr">33</xref>].</p></sec><sec id="sec3-pharmaceutics-17-00225"><title>3. MOFs as Drug Delivery Carriers for Tumor Immunotherapy</title><sec id="sec3dot1-pharmaceutics-17-00225"><title>3.1. Tumor Immunity Activation Effect of MOFs</title><p>As a kind of potential carrier material for antitumor drugs, MOFs&#x02019; antitumor immunity activation ability has been progressively found by researchers. Notably, the induction of ferroptosis by iron ions is a mechanism which has been well-recognized. For instance, Du et al. developed a delivery system, denoted as COS@MOF, where MIL-88B(Fe) was etched by thiamine pyrophosphate (TPP) and modified with oligo-chitosan. This system exerted a nano-enzyme effect upon internalization by colorectal cancer cells [<xref rid="B34-pharmaceutics-17-00225" ref-type="bibr">34</xref>]. This led to the depletion of glutathione (GSH), thus inhibiting the activity of glutathione peroxidase 4 (GPX4) and inducing ferroptosis. Concurrently, Fe<sup>2+</sup> released by COS@MOF accelerated the conversion of H<sub>2</sub>O<sub>2</sub> into hydroxyl radicals, thereby contributing to the cytotoxicity against tumor cells (<xref rid="pharmaceutics-17-00225-f004" ref-type="fig">Figure 4</xref>a). Nevertheless, the immune activation effects of this mechanism warrant further investigation. The study conducted by Ploetz et al. had corroborated this deduction [<xref rid="B35-pharmaceutics-17-00225" ref-type="bibr">35</xref>]. They conducted a drug delivery system named Lip-MOF by MIL-100(Fe), coated with DOPC. Upon cellular uptake, the released Fe<sup>2+</sup> not only induced apoptosis in tumor cells but also activated the caspases-dependent pathway, causing the release of gasdermin (GSDM) and the production of IL-1&#x003b2;. The Fe<sup>2+</sup> also initiated an inflammatory form of programmed cell death and subsequently stimulated the immune system to mount an antitumor response. The immunostimulatory effects of Fe-MOFs have aroused extensive interest. Inspired by this, whether MOFs composed of other metals, such as commonly utilized Mn-MOFs, Zn-MOFs, and Cu-MOFs, exhibit analogous antitumor immune responses has attracted researchers&#x02019; interest. Liu et al. conducted a drug delivery system, denoted as Mn-MOF@PEG, by modifying Mn-MOFs with PEG for pancreatic cancer [<xref rid="B36-pharmaceutics-17-00225" ref-type="bibr">36</xref>]. The findings indicated that Mn<sup>2+</sup> could increase the percentage of DCs and promote their maturation in the TME, thus enhancing the tumor immune profile. Ding et al. [<xref rid="B37-pharmaceutics-17-00225" ref-type="bibr">37</xref>] explored the immunity activation effects of Zn-MOFs, specifically ZIF-8 nanoparticles (NPs), and found that ZIF-8 NPs responsively released Zn<sup>2+</sup>, inducing a sudden surge in ionic concentration and intracellular osmotic pressure. As a result, the cysteine-aspartate-specific protease-1 (Caspase-1)/gasdermin D (GSDMD)-dependent pyroptotic pathway was activated to achieve antitumor immune response.</p><p>The tumor immunity activation of monometallic MOFs has been widely validated; therefore, the inclusion of multiple metal types in MOFs may elicit synergistic antitumor immune responses. Dai et al. [<xref rid="B38-pharmaceutics-17-00225" ref-type="bibr">38</xref>] constructed bimetallic MOFs, named Gd-MOF-5, which could release both Gd<sup>3+</sup> and Zn<sup>2+</sup> in murine breast cancer 4T1 cells. Gd<sup>3+</sup> competed with Ca<sup>2+</sup> to bind TMEM 16F, a Ca<sup>2+</sup>-gated ion channel, leading to its inactivation and the inhibition of phosphatidylserine (PS) externalization. Additionally, the overload of Zn<sup>2+</sup> induced mitochondrial dysfunction, activated endoplasmic reticulum (ER) stress, and disrupted cellular calcium homeostasis, finally leading to ICD. These two types of metal ions individually induced tumor immunity activation via two distinct pathways, resulting in significantly enhanced outcomes in cancer immunotherapy. Yan et al. [<xref rid="B39-pharmaceutics-17-00225" ref-type="bibr">39</xref>] further developed trimetallic MOFs composed of Cu, Au, and Zn, and loaded with photosensitizer purpurin 18 (P18), to fabricate an immunostimulatory nanoreactors denoted as ACS-Z-P NPs. Upon laser irradiation, a sudden release of Zn<sup>2+</sup> induced Caspase 1/GSDMD-dependent pyroptosis and ICD. Concurrently, the active site Au-Cu2-xSe facilitated the production of reactive oxygen species (ROS) through a Cu-mediated Fenton reaction, thereby triggering the activation of inflammatory cells. As a result, damage-associated molecular patterns (DAMPs) were released and, in turn, synergistic immunity activation effects were initiated, leading to the reshape of TIEM.</p><p>In summary, the antitumor immunity induced by MOFs is primarily contingent upon the metal ions they contain. On the one hand, the degradation of MOFs can release metal ions, leading to a sudden increase in intracellular osmotic pressure, thereby activating the pyroptosis pathway. On the other hand, MOFs catalyze the generation of ROS with their functions as nanozymes, inducing cell pyroptosis, and activating antitumor immunity. The antitumor immunogenicity of MOFs augments their advantage as antitumor drug carriers, and the subsequent loading of various immunostimulatory agents holds the promise of a synergistic effect greater than the sum of parts, delivering better tumor immunotherapy outcomes.</p></sec><sec id="sec3dot2-pharmaceutics-17-00225"><title>3.2. MOFs as Carriers of Chemotherapeutic Drugs for Cancer Immunotherapy</title><p>Although chemotherapy is a paramount therapeutic modality for clinical tumor treatment, its immunosuppressive side effects significantly diminish its efficacy. Recent studies have indicated that certain chemotherapeutic drugs, such as doxorubicin (DOX) [<xref rid="B40-pharmaceutics-17-00225" ref-type="bibr">40</xref>], oxaliplatin [<xref rid="B41-pharmaceutics-17-00225" ref-type="bibr">41</xref>], and paclitaxel (PTX) [<xref rid="B42-pharmaceutics-17-00225" ref-type="bibr">42</xref>], can active tumor immunity by inducing immunogenic cell death. The pro-apoptotic effects of chemotherapy drugs combined with continuous tumor immunity activation would synergistically achieve continuous killing of tumor cells. Since MOFs can effectively activate antitumor immunity, utilizing MOFs as carriers of chemotherapeutic agents will achieve dual effects of drug delivery and immunity activation. The expansive drug-loading capacity and unique pH responsiveness of MOFs render them ideal carriers for chemotherapeutic drug to achieve enhanced tumor immunotherapy effects. As a representative, Fe-MOFs loaded with chemotherapeutic agents effectively achieve synergistic efficacy of chemotherapy and ferroptosis. Moreover, cunningly selected organic ligands (such as the carbonic anhydrase IX (CA IX) inhibitor&#x02014;fumarate [<xref rid="B43-pharmaceutics-17-00225" ref-type="bibr">43</xref>]) or combinations with other metals (such as Mn [<xref rid="B44-pharmaceutics-17-00225" ref-type="bibr">44</xref>]) can promote ferroptosis or amplify immune effects, yielding superior antitumor efficacy. In addition to relying on Fe-MOFs, MOFs based on other metal can also activate ferroptosis pathways by loading with corresponding chemotherapeutic agents. For example, Yang et al. employed Zn-MOFs loaded with dihydroartemisinin (DHA) and CORM-401 for the treatment of colorectal cancer [<xref rid="B45-pharmaceutics-17-00225" ref-type="bibr">45</xref>]. Both DHA and CORM-401 induced ferroptosis and elevated ROS levels to promote apoptosis, thereby releasing tumor-associated antigens (TAAs) and DAMPs to promote DC maturation and activation of CLTs, and finally achieved sustained and potent antitumor effects (<xref rid="pharmaceutics-17-00225-f004" ref-type="fig">Figure 4</xref>b).</p><fig position="anchor" id="pharmaceutics-17-00225-f004"><label>Figure 4</label><caption><p>(<bold>a</bold>) Schematic diagram of COS@MOF with a nano-enzyme effect upon internalization by colorectal cancer cells. Reproduced with permission [<xref rid="B34-pharmaceutics-17-00225" ref-type="bibr">34</xref>]. Copyright 2023, Wiley-VCH GmbH. (<bold>b</bold>) Schematic illustration of the synthesis process of PMDC NPs and their effects on tumor immunotherapy. Reproduced with permission [<xref rid="B45-pharmaceutics-17-00225" ref-type="bibr">45</xref>]. Copyright 2024, Elsevier B.V.</p></caption><graphic xlink:href="pharmaceutics-17-00225-g004" position="float"/></fig><p>Caspase-3 is one of the key proteins in the cell pyroptotic pathway, and the activation of it elicits the upregulation of the tumor suppressor gene gasdermin E (GSDME) and activates the pyroptosis switch in cancer cells. This process leads to the formation of GSDME-N aggregates, perforating the cell membrane, and finally resulting in cell swelling, lysis, and death, with the concomitant release of inflammatory cytokines that activate antitumor immunity [<xref rid="B46-pharmaceutics-17-00225" ref-type="bibr">46</xref>]. Certain chemotherapeutic agents can counteract the immunosuppressive effects of chemotherapy by activating the Caspase-3/GSDME pathway and achieve improved therapeutic efficacy. For example, Zhou et al. [<xref rid="B47-pharmaceutics-17-00225" ref-type="bibr">47</xref>] constructed a nanotherapeutic system, denoted as (M+H)@ZIF/HA, by loading the chemotherapeutic drug mitoxantrone (MIT) and the DNA-demethylating agent hydrazine (HYD) into Zn-MOFs and modifying it with HA. HYD and MIT effectively activated the Caspase-3/GSDME-signaling pathway and initiated the pyroptotic program, inhibiting T cell paralysis mediated by myeloid-derived suppressor cells (MDSCs). As a result, the TME transformed from &#x0201c;cold&#x0201d; to &#x0201c;hot&#x0201d;, and the tumor was converted into an antigen repository, thereby leading to a robust antitumor immune response and significant tumors elimination in a breast cancer mouse model. Similarly, Wu et al. [<xref rid="B48-pharmaceutics-17-00225" ref-type="bibr">48</xref>] prepared a tumor-targeted delivery system, MTX-PEG@TPL@ZIF-8, by loading the chemotherapeutic drug triptolide (TPL) into Zn-MOFs and encapsulating methotrexate-polyethylene glycol conjugates (MTX-PEG). MTX facilitated tumor targeting and accumulation, and Zn-MOFs achieved the pH-responsive release of TPL and MTX in triple-negative breast cancer (TNBC). The release of TPL and MTX could promote cell death via cleaved Caspase-9 and cleaved Caspase-3 upregulating. Apart from loading with agents that activate the Caspase-3 pathway, certain MOFs also active Caspase-3 directly by releasing metal ions. For example, Wang et al. loaded DOX into Zr-MOFs for cancer treatment, and results showed that DOX and Zr<sup>4+</sup> synergically activated the Caspase-3/GSDME signaling pathway and induced rapid pyroptosis [<xref rid="B49-pharmaceutics-17-00225" ref-type="bibr">49</xref>]. This system presented superb systemic antitumor immune effect when combined with PD-1 checkpoint blockade.</p><p>In addition, MOFs can response to light or ultrasound stimuli. MOFs loaded with chemotherapy drugs combined with light or ultrasound elicit potent antitumor immune response. Inspired by this paradigm, Xing et al. [<xref rid="B50-pharmaceutics-17-00225" ref-type="bibr">50</xref>] developed a micro-robot, denoted as IDN@MC, by loading decitabine, a chemotherapeutic agent, into ZIF-8. The drug-loaded NPs were subsequently phagocytosed by macrophages. Laser induced rapid and long-lasting antitumor immune response via Caspase-3-dependent GSDME-associated pyroptosis, thus modulating the tumor immunosuppressive microenvironment. Similarly, Yang et al. [<xref rid="B51-pharmaceutics-17-00225" ref-type="bibr">51</xref>] employed Ti-MOFs to encapsulate cisplatin. Combined with sonodynamic stimulation, this delivery system could effectively active antitumor immune and transform the TIME from &#x0201c;cold&#x0201d; to &#x0201c;hot&#x0201d;, thereby suppressing primary tumors and metastases formation.</p></sec><sec id="sec3dot3-pharmaceutics-17-00225"><title>3.3. MOFs as Carriers of Immunomodulator for Tumor Immunity Activation</title><p>TME is in an immunosuppressive condition, and the employment of immunomodulators is a direct approach to activating the immune system, which will elicit a more immediate and potent antitumor immune response, thereby prompting the effective elimination of cancer cells. MOFs as carriers of immunomodulators tend to achieve better tumor immunotherapy effects.</p><sec id="sec3dot3dot1-pharmaceutics-17-00225"><title>3.3.1. MOFs as Carriers of Innate Immune Molecular Receptor Agonists</title><p>As an integral component of the immune system, the innate immune pathway is widely present in most cells, which can provide significant potential for enhancing the TIME [<xref rid="B52-pharmaceutics-17-00225" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-17-00225" ref-type="bibr">53</xref>]. The heterogeneity of the innate immune pathway in the TME, associated with development stage, pathway status, and specific cell types, holds promise for targeting innate immunity in tumor immunotherapy. Notably, the toll-like receptor (TLR) pathway and the cyclic GMP&#x02013;AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway are prominent in the antitumor domain.</p><p>TLRs are widely expressed in the spectrum of immune cells, and their activation leads to MyD88- or TRIF-dependent signaling pathways, which further activate NF-&#x003ba;B and innate and adaptive immune responses, improving the efficacy of tumor immunotherapy. Drug delivery systems with MOFs as drug carriers and TLR agonists as active pharmaceutical ingredients (API) can combine the immunity activation effects of both TLR pathway and MOFs, showcasing synergistic efficacy. For example, Feng et al. [<xref rid="B54-pharmaceutics-17-00225" ref-type="bibr">54</xref>] developed a tumor-targeted drug delivery system, called FeMn@R@H, by using Fe/Mn-MOFs as carriers and TLR agonist resiquimod (R848) as API, and modified the NPs with HA. R848 activated TLR 7/8, triggering downstream pathways, and the substantial release of Fe<sup>3+</sup> and Mn<sup>2+</sup> increased ROS and reduced GSH, inducing cell pyroptosis. As a result, FeMn@R@H could promote DC maturation and facilitate the conversion of macrophages from M2 to M1 phenotype, effectively reversing the suppressive TIME and achieving enhanced tumor immunotherapy effects (<xref rid="pharmaceutics-17-00225-f005" ref-type="fig">Figure 5</xref>a). Similarly, Pang et al. [<xref rid="B55-pharmaceutics-17-00225" ref-type="bibr">55</xref>] fabricated drug delivery systems, denoted as isMOFs, which were Zr-MOFs carried with the TLR 9 agonist single-stranded DNA CpG. Subsequently, isMOFs were modified with antiresorptive bisphosphonate, zoledronic acid (ZOL) called BT-isMOFs on the surface. The release of CpG activated TLR 9 and exerted a strong immunostimulatory effect, finally promoting macrophage conversion from M2 to M1 phenotype, thus effectively ameliorating breast cancer-associated osteolysis.</p><p>The cGAS-STING-signaling pathway is another crucial immunostimulatory pathway of the innate immune system. cGAS is located in the cytoplasm. Upon activation by double-stranded DNA (dsDNA), cGAS promotes cGAMP synthesis, thereby activating the STING dimer on the endoplasmic reticulum and initiating downstream pathways to express pro-inflammatory cytokines [<xref rid="B56-pharmaceutics-17-00225" ref-type="bibr">56</xref>]. The cGAS-STING pathway has been implicated in various stages of the cancer immune cycle, such as inducing cancer cell death, enhancing antigen processing and presentation, promoting T cell activation and tumor infiltration, and facilitating T cell recognition and clearance of cancer cells. Delivery systems based on MOFs can achieve tumor-targeted STING agonists delivery, showing excellent antitumor immune effects. Luo et al. [<xref rid="B57-pharmaceutics-17-00225" ref-type="bibr">57</xref>] loaded the STING agonist 2,3-cyclic GMP-adenosine monophosphate (GA) into Hf-MOFs, constructing a GA-MOF delivery system. GA-MOFs exhibited potent and sustained STING activation effects and could transform tumors into immune hotspots in conjunction with the immune checkpoint inhibitor &#x003b1;PD-L1, achieving excellent systemic immunity activation and distant tumor suppression effects. In addition to the employment of STING agonists, the activation of cGAS/STING pathways induced by other pathways can provide synergistically enhanced effects. Xu et al. [<xref rid="B58-pharmaceutics-17-00225" ref-type="bibr">58</xref>] developed a delivery system denoted as S@Cu-MOF/PPI by loading polyphenol I (PPI) into spiky Cu-MOFs. The release of Cu<sup>2+</sup> induced cuproptosis, and PPI triggered cell apoptosis and mitochondrial damage, and subsequently activated the cGAS/STING pathway. These influences synergistically reversed the TIME and significantly eliminated primary tumors and inhibiting the growth of distant tumors.</p><p>Furthermore, the concurrent activation of the TLR pathway and STING pathway, as demonstrated by Chen et al. [<xref rid="B59-pharmaceutics-17-00225" ref-type="bibr">59</xref>], also achieved good tumor immunotherapy effect. They prepared a delivery system named MOF-CpG-DMXAA by using Zr-MOFs as drug carriers and CpG and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) as APIs. DMXAA acted as both a STING agonistic and angiogenic inhibitor. CpG activated TLR4 and downstream pathways, and DMXAA inhibited angiogenesis, achieving starvation therapy, and activated STING pathway. Together, they achieved the effects of DC maturation and tumor-associated macrophages (TAMs) reprogramming, and triggered the systemic immunity activation, thus stimulating a potent antitumor immune response.</p></sec><sec id="sec3dot3dot2-pharmaceutics-17-00225"><title>3.3.2. MOFs as Vectors for Kinase Inhibitors</title><p>Kinases mediate phosphorylation of proteins, thus play a pivotal &#x0201c;switch&#x0201d; role in the whole physiological processes of cells, such as proliferation, apoptosis, migration, and inflammation. The translocation or mutation of kinases may induce the occurrence of cancers, positioning them as potential drug targets. Certain kinase inhibitors can effectively induce immunity activation, thereby exerting tumoricidal effects. The employment of MOFs as vectors of kinase inhibitors in tumor immunotherapy has emerged as a popular research focus [<xref rid="B60-pharmaceutics-17-00225" ref-type="bibr">60</xref>].</p><p>Zhang et al. [<xref rid="B61-pharmaceutics-17-00225" ref-type="bibr">61</xref>] developed a delivery system, CZFNP, by loading the cyclooxygenase-2 (COX-2) inhibitor C-phycoerythrin (CPC) into ZIF-8 NPs. This system swiftly released Zn<sup>2+</sup> and CPC in the TME. Zn<sup>2+</sup> induced mitochondrial damage and mtDNA release to activate the cGAS-STING pathway, and CPC inhibited COX-2 and increased the release of prostaglandin E2 (PGE2). The synergistic therapy activated the immune system and transformed the TIME from &#x0201c;cold&#x0201d; to &#x0201c;hot&#x0201d;, thereby enhancing the therapeutic effects of tumor immunotherapy (<xref rid="pharmaceutics-17-00225-f005" ref-type="fig">Figure 5</xref>b). Wang et al. [<xref rid="B62-pharmaceutics-17-00225" ref-type="bibr">62</xref>] used Gd/Fe-MOFs to deliver the tyrosine kinase inhibitor lenvatinib (LEN) and combined with microwave (MW) hyperthermia for tumor immunotherapy. MW increased the sensitivity of Gd/Fe-MOFs, promoting the production of ROS and ICD. LEN inhibited the activity of fibroblast growth factor receptor 4 (FGFR4) and then facilitated the degradation of programmed death receptor ligand 1 (PD-L1), driving the reprogramming of the TME and activating the immune response to exert tumoricidal effects.</p></sec><sec id="sec3dot3dot3-pharmaceutics-17-00225"><title>3.3.3. MOFs as Carriers for Immune Checkpoint Inhibitors</title><p>Immune checkpoints (ICs) are a series of molecules that regulate the degree of immune activity to prevent excessive activation, playing the role of immune &#x0201c;brake&#x0201d; [<xref rid="B63-pharmaceutics-17-00225" ref-type="bibr">63</xref>]. However, tumor cells express certain substances to activate immune checkpoints, inhibiting the antigen presentation process and achieving immune evasion. Immune checkpoint therapy (ICT) can remove the suppression effects of tumor cells to immune cells by using immune checkpoint inhibitors (ICIs), ensuring the smooth activation of immune cells and exerting their tumoricidal effects. ICT has offered substantial opportunities and even chances of cure for clinical cancer patients [<xref rid="B64-pharmaceutics-17-00225" ref-type="bibr">64</xref>].</p><p>Currently, several ICIs have been marketed, primarily divided into two categories, which are inhibitors for cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and those for programmed death receptor 1 (PD-1)/PD-L1. aPD-1 is a commonly used PD-1 model inhibitor, which can directly recognize and bind to PD-1, thereby unblocking immune cell brakes. Cui [<xref rid="B65-pharmaceutics-17-00225" ref-type="bibr">65</xref>] et al. loaded aPD-1 within Gd- MOF to obtain a Gd/MPC delivery system. This system showed significant activation of T cells and led to the recognition and elimination of tumor cells. Aptamers are a class of RNA or DNA nucleotides that can bind to targets with high affinity. In addition to antibodies, aptamers can also target the PD-1/PD-L1 axis and exhibit the ability to release the immune &#x0201c;brake&#x0201d; [<xref rid="B66-pharmaceutics-17-00225" ref-type="bibr">66</xref>]. Furthermore, MOF delivery systems with special nanostructure whose convex vertex exerted PD-L1 aptamer effects could also effectively block the immune suppression caused by the PD-1/PD-L1, thus activating the TME immune response [<xref rid="B67-pharmaceutics-17-00225" ref-type="bibr">67</xref>] (<xref rid="pharmaceutics-17-00225-f005" ref-type="fig">Figure 5</xref>c).</p><fig position="anchor" id="pharmaceutics-17-00225-f005"><label>Figure 5</label><caption><p>(<bold>a</bold>) Schematic illustration of synthesis tactics and molecular mechanism of FeMn@R@H against tumors. Reproduced with permission [<xref rid="B54-pharmaceutics-17-00225" ref-type="bibr">54</xref>]. Copyright 2023, Elsevier B.V. (<bold>b</bold>) Harnessing stimulator of interferon genes (STING) and cyclooxygenase-2 (COX-2) signal by steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy. Reproduced with permission [<xref rid="B61-pharmaceutics-17-00225" ref-type="bibr">61</xref>]. Copyright 2024, Elsevier Ltd. (<bold>c</bold>) Schematic illustration showing the preparation process and therapeutic mechanism of CPD@M-TDN. Reproduced with permission [<xref rid="B67-pharmaceutics-17-00225" ref-type="bibr">67</xref>]. Copyright 2024, Elsevier B.V. (<bold>d</bold>) Schematic illustration of the fabrication and mechanism to induce pyroptosis of <sup>F127</sup>ZIF-8<sub>CCCP</sub> nanoparticles for cancer immunotherapy. Reproduced with permission [<xref rid="B37-pharmaceutics-17-00225" ref-type="bibr">37</xref>]. Copyright 2023, Wiley-VCH GmbH.</p></caption><graphic xlink:href="pharmaceutics-17-00225-g005" position="float"/></fig><p>Indoleamine 2,3-dioxygenase (IDO) can catalyze the metabolism of tryptophan. The high expression of IDO in tumor cells leads to depletion of tryptophan in the TME, inhibiting the function of tryptophan-sensitive T cells and thereby causing immune evasion. Herein, we may also consider IDO as a type of ICs. MOFs loaded with IDO inhibitor could effectively reduce IDO activity and achieve immune system activation, thus providing significant tumor inhibition effects [<xref rid="B68-pharmaceutics-17-00225" ref-type="bibr">68</xref>]. Similarly, signal regulatory proteins (SIRPs) are another site for tumor cells to evade immune surveillance, as tumor cells express CD47 to specifically bind to macrophages and prevent their phagocytosis. When &#x003b1; CD47, a CD47 antibody, was loaded into Al-MOFs for cancer treatment, it could bind to CD47 on the surface of cancer cells, relieving CD47 signal-blocking and leading to immunity activation [<xref rid="B69-pharmaceutics-17-00225" ref-type="bibr">69</xref>].</p></sec><sec id="sec3dot3dot4-pharmaceutics-17-00225"><title>3.3.4. MOFs as Carriers of Programmed Cell Death Inducers</title><p>Programmed cell death (PCD) includes apoptosis, autophagy, and pyroptosis, as well as ferroptosis and cuproptosis, have been identified in recent years. PCD inducers can effectively induce one or several corresponding PCD, exerting antitumor effects. Metal ions released from MOFs have the potential to induce PCD; therefore, MOFs- as PCD-inducer carriers further amplify the PCD effects to achieve a synergistic antitumor immune activation.</p><p>Pyroptosis is a kind of lysate and inflammatory programmed cell death pathway different from apoptosis, which induces a strong inflammatory response and contribute to tumor regression [<xref rid="B70-pharmaceutics-17-00225" ref-type="bibr">70</xref>]. The inherent capacity of MOFs to induce pyroptosis will amplify the pyroptotic signaling when combined with pyroptosis inducers, contributing to the stimulation of antitumor immunity and the enhancement of antitumor efficacy. This was confirmed by the study of Ding et al. [<xref rid="B37-pharmaceutics-17-00225" ref-type="bibr">37</xref>], where a delivery system, denoted as F127ZIF-8CCCP, was developed by loading cyanoacetate m-chlorophenylhydrazone (CCCP) into ZIF-8 and modifying their surface with Pluronic F127. Zn<sup>2+</sup> worked as the pyroptotic inducer by activating the Caspase-1/GSDMD pathway, and CCCP elevated ROS levels and magnified the pyroptotic signal, finally leading to synergistic anticancer immunotherapy (<xref rid="pharmaceutics-17-00225-f005" ref-type="fig">Figure 5</xref>d). Cuproptosis is a novel mode of cell death caused by excess intracellular coppers, and it mainly functions through the degradation of Fe-S cluster proteins and proteotoxic responses by stimulating the sulfur-acylation aggregation process of mitochondria-related proteins [<xref rid="B71-pharmaceutics-17-00225" ref-type="bibr">71</xref>]. Similarly to the above study, Cu-MOFs successfully induced cuproptosis, and the cuproptosis-inducer elisomol (ES) augmented this effect, leading to strong ICD and reshaping the TIME. As a result, this Cu-MOFs based-delivery system effectively inhibited the growth of breast tumors [<xref rid="B72-pharmaceutics-17-00225" ref-type="bibr">72</xref>].</p></sec></sec><sec id="sec3dot4-pharmaceutics-17-00225"><title>3.4. MOFs as Carriers of Enzyme for TIME Reversal</title><p>The tumor microenvironment is characterized by features such as hypoxia, acidity, and elevated ROS levels, which play a key role in tumor immunosuppression. Some of these features can inhibit the activity of immune cells and facilitate tumor immune evasion. For example, a relatively low pH may induce cell acidosis and lead to the hematogenous and lymphatic spread of tumor cells, thus worsening the long-term prognosis of patients [<xref rid="B73-pharmaceutics-17-00225" ref-type="bibr">73</xref>].</p><p>The reduced pH in the TME is primarily due to lactate (LA) accumulation. As a product of tumor cell metabolism, LA has been recently identified to act as an &#x0201c;accomplice&#x0201d; of tumor. LA binds to Alanyl-tRNA synthetase 1 (AARS1) to catalyze the formation of LA-AMP complex that promotes the lactylation of the p53 protein, leading to its dysregulation. This, in turn, hampers cell cycle regulation and stimulates tumor growth, thereby facilitating the invasiveness, metastasis, angiogenesis, and immune evasion of cancer cells [<xref rid="B74-pharmaceutics-17-00225" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceutics-17-00225" ref-type="bibr">75</xref>]. The introduction of lactate-metabolizing enzymes into the TME can effectively reduces LA levels, presenting a promising strategy for antitumor immunity activation. This was confirmed by the study of Zhou et al. [<xref rid="B76-pharmaceutics-17-00225" ref-type="bibr">76</xref>]. Lactate oxidase (LOX) loaded within Zn-MOFs depleted the LA levels in the TME and restored vascular normalization, promoting the infiltration of CTL. In another study, LOX was co-delivered with small interfering RNA (siRNA) targeted against monocarboxylate transporter 4 (MCT4) by Fe-MOFs [<xref rid="B77-pharmaceutics-17-00225" ref-type="bibr">77</xref>]. LOX catalyzed the metabolism and siRNA inhibited the efflux of LA, leading to a synergetic LA-reduced and activated immune system.</p><p>Another major feature of the TME is the increased GSH. As a critical regulator of tumorigenesis, progression, and metastasis, GSH aids in the elimination of ROS and reduces the sensitivity of tumor cells to oxidative stress [<xref rid="B78-pharmaceutics-17-00225" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceutics-17-00225" ref-type="bibr">79</xref>]. The hypoxia phenomenon is also worthy of attention. Hypoxic conditions activate the hypoxia-inducible factor 1&#x003b1; (HIF-1&#x003b1;) which enables tumor cells to survive at lower oxygen levels. As a result, the proliferation, invasion, and metastatic capabilities of cancer cells are improved and the immunosuppression of the TME is enhanced [<xref rid="B80-pharmaceutics-17-00225" ref-type="bibr">80</xref>]. Catalase (CAT) positively influences both factors by reducing GSH levels and alleviating hypoxia [<xref rid="B81-pharmaceutics-17-00225" ref-type="bibr">81</xref>]. When combined with MOFs, its immune-boosting effect was further reinforced. The drug system based on Cu-MOFs loaded with CAT triggered cuproptosis to induce ICD, depleted GSH, and promoted H<sub>2</sub>O<sub>2</sub> decomposition into O<sub>2</sub> to relieve hypoxia, effectively reversing TIME suppression [<xref rid="B82-pharmaceutics-17-00225" ref-type="bibr">82</xref>]. CAT loaded in Zn-MOFs showed similar antitumor immunotherapy effects [<xref rid="B83-pharmaceutics-17-00225" ref-type="bibr">83</xref>] (<xref rid="pharmaceutics-17-00225-f006" ref-type="fig">Figure 6</xref>a).</p><p>Apart from the enzymes aiming for the balance of the TME, other enzymes can also stimulate antitumor immune response through certain catalytic actions on intracellular substances. For example, Yang et al. [<xref rid="B84-pharmaceutics-17-00225" ref-type="bibr">84</xref>] delivered glucose oxidase (GOx) by cancer cell membrane-coated Fe-MOFs for cancer treatment. GOx catalyzed glucose to produce H<sub>2</sub>O<sub>2</sub>, leading to ROS generation and subsequently inducing ICD.</p></sec><sec id="sec3dot5-pharmaceutics-17-00225"><title>3.5. MOFs as Carriers of Oligonucleotide Drugs to Overcome Immunotherapy Tolerance</title><p>Oligonucleotide drugs, also known as small nucleic acid drugs, include siRNA, microRNA (miRNA), and antisense oligonucleotides (ASO), among others. Oligonucleotide drugs achieve therapeutic effects through specifically silencing the expression of disease genes; therefore, they have the capacity to develop agents for untargetable or undruggable diseases [<xref rid="B85-pharmaceutics-17-00225" ref-type="bibr">85</xref>]. Specifically designed siRNA or miRNA can downregulate the expression of proteins. while circular DNA drugs can introduce target genes into specific cells to elevate protein levels, thereby exerting effects on targets. The silencing or activation effects of immune responses contribute to antitumor efficacy. MOFs, with positively charged surfaces and expansive internal cavities, serve as ideal carriers for nucleic acid drugs, protecting them from enzymatic hydrolysis, increasing their loading, and promoting lysosomal escape [<xref rid="B86-pharmaceutics-17-00225" ref-type="bibr">86</xref>].</p><p>siRNA, composed of 21&#x02013;23 nucleotide-long double-stranded RNA molecules, can integrate into the RNA-induced silencing complex (RISC) and lead to the degradation of the passenger strand (sense strand), thus inducing the subsequent post-transcriptional gene silence and effectively reducing target protein levels [<xref rid="B87-pharmaceutics-17-00225" ref-type="bibr">87</xref>]. As introduced above, Cu-MOFs have the ability to trigger cuproptosis [<xref rid="B58-pharmaceutics-17-00225" ref-type="bibr">58</xref>,<xref rid="B72-pharmaceutics-17-00225" ref-type="bibr">72</xref>]. Similarly, Fe-MOFs can induce ferroptosis. Sun et al. employed Fe/Zr-MOFs to load siRNA-targeting glutathione peroxidase 4 (GPX 4), constructing a biomimetic nanomedicine delivery system named mFeP@si [<xref rid="B88-pharmaceutics-17-00225" ref-type="bibr">88</xref>]. The release of Fe<sup>2+</sup> increased ROS levels and led to ferroptosis. siGPX4 silenced GPX 4 expression and caused the accumulation of toxic phospholipid hydroperoxides (PL-OOH), thus amplifying the ROS storm. As a result, this delivery system induced robust ICD and reversed the immunosuppressive TME, enhancing antitumor immune effects (<xref rid="pharmaceutics-17-00225-f006" ref-type="fig">Figure 6</xref>b). In another study, siRNA targeting ataxia-telangiectasia and rad3-related (ATR) and the chemotherapeutic drug DOX were co-loaded in ZIF-8 NPs to modulate tumor gene expression profiles. DOX induced DNA damage to tumor cells, and siATR silenced the expression of ATR protein, inhibiting DNA repair. The viability of tumor cells was reduced, and their immunogenicity was increased. As a result, the TME was transformed from suppressive to activated, achieving combined chemotherapy and immune stimulation for pancreatic cancer [<xref rid="B89-pharmaceutics-17-00225" ref-type="bibr">89</xref>].</p><p>miRNA is a type of oligonucleotide drug that consists of 19&#x02013;25 nucleotide-long double-stranded RNA molecules. Similarly to siRNA, miRNA drugs also aim for the reduction in protein expression levels. The difference is that miRNA can silence the target through RISC or induce mRNA degradation by direct binding [<xref rid="B90-pharmaceutics-17-00225" ref-type="bibr">90</xref>]. Cui et al. developed a delivery system, denoted as OMV@ZIF@pre-miRNA, by loading miRNA within ZIF-8 and coating with bacterial outer membrane vesicles (OMV-PD-1) that specifically express PD-1 [<xref rid="B91-pharmaceutics-17-00225" ref-type="bibr">91</xref>]. PD-1, on the surface, mediated precise tumor targeting and triggered the immune checkpoint inhibition to activate antitumor immunity. miR-34a inhibited the translation of the target mRNA, causing cell cycle arrest and effectively eliminating tumors.</p><p>In addition, traditional plasmids and circular DNA also play a significant role in antitumor immunotherapy by introducing the desired genes. In another research, Zhao et al. constructed a gene delivery system using Fe-MOFs MIL-88A loaded with minicircle DNA [<xref rid="B92-pharmaceutics-17-00225" ref-type="bibr">92</xref>]. The minicircle DNA stably expressed bispecific T cell engager (BiTE) anti-CD3/anti-EpCAM, thus enhancing tumor localization and CTLs recognition, significantly inhibiting tumor growth.</p></sec><sec id="sec3dot6-pharmaceutics-17-00225"><title>3.6. MOFs as Carriers of Tumor Vaccines for Immune Stimulation</title><p>Tumor vaccines have emerged as a pivotal strategy in tumor immunotherapy. Tumor vaccines achieve suppression of tumor progression via releasing antigen to stimulate the immune system and eliminate tumor cells. As clinical trials advance, the efficacy of tumor vaccines is increasingly being validated [<xref rid="B93-pharmaceutics-17-00225" ref-type="bibr">93</xref>]. For a tumor vaccine to exert potent antitumor immunity activation, it is necessary to complete the process of tumor antigen uptake and presentation by DCs, CTLs activation, and the subsequent recognition and destruction of tumor cells by CTLs. However, the immune evasion mechanisms in the TME, such as immune checkpoint inhibition and antigen presentation restriction, significantly impede the efficacy of tumor vaccines [<xref rid="B94-pharmaceutics-17-00225" ref-type="bibr">94</xref>]. Effectively achieving antigen presentation has become the key to tumor vaccines.</p><p>A more direct solution is to increase the antigen levels targeting and accumulating in the tumor site. Ovotransferrin (OVA) is a commonly used antigen model. Delivery systems based on OVA as a major API and MOFs as carriers have shown significant effects on prompting DC maturation and CTL activation, thus stimulating robust tumor-specific immune responses and leading to significant anticancer effects against both primary and distant tumors [<xref rid="B95-pharmaceutics-17-00225" ref-type="bibr">95</xref>,<xref rid="B96-pharmaceutics-17-00225" ref-type="bibr">96</xref>] (<xref rid="pharmaceutics-17-00225-f006" ref-type="fig">Figure 6</xref>c). In addition to model antigen vaccines, the whole cell cancer vaccines (WCCVs), which use tumor cells as vaccines, contain a full array of tumor-associated antigens (TAAs), thereby activating more comprehensive and potent antitumor immune responses [<xref rid="B97-pharmaceutics-17-00225" ref-type="bibr">97</xref>]. Yang et al. built novel WCCVs by forming a ZIF-8 shell on tumor cells [<xref rid="B98-pharmaceutics-17-00225" ref-type="bibr">98</xref>]. Upon ICD of tumor cells, calreticulin (CRT) was exposed and TAAs were released at relative high levels, inducing robust tumor immunity activation.</p><p>Beside the above solutions, increasing the antigen presentation efficacy is an alternative way to improve the immunity activation effects of tumor vaccines. For example, Zhang et al. constructed tumor nanovaccine, denoted as NMCAH, based on Fe-MOFs by loading arachidonic acid (AA) and coating 1,3,5-benzenetricarboxaldehyde (TBP), p-phenylenediamine (PDA), and HA [<xref rid="B99-pharmaceutics-17-00225" ref-type="bibr">99</xref>]. This nanovaccine could improve the tumor immunogenic by triggering and amplifying the ferroptosis effects and lead to the activation of antitumor immunity and tumor-killing effects (<xref rid="pharmaceutics-17-00225-f006" ref-type="fig">Figure 6</xref>d). Liu et al. developed a biomimetic nanovaccine based on Mn/Zr-MOFs encapsulating tumor cell membranes (CM) with Ythdf1-targeted short hairpin RNA (shY1) [<xref rid="B100-pharmaceutics-17-00225" ref-type="bibr">100</xref>]. The gradual release of TAAs, shY1, and Mn<sup>2+</sup> synergistically activated the cGAS/STING immune pathway, increasing cross-presentation, thus inducing potent antitumor immune response.</p><fig position="anchor" id="pharmaceutics-17-00225-f006"><label>Figure 6</label><caption><p>(<bold>a</bold>) Illustration of the synthesis of nanomedicine and the therapeutic mechanism. Reproduced with permission [<xref rid="B83-pharmaceutics-17-00225" ref-type="bibr">83</xref>]. Copyright 2024, Elsevier Ltd. (<bold>b</bold>) Schematic of the preparation and therapeutic mechanism of mFeP@si. Reproduced with permission [<xref rid="B88-pharmaceutics-17-00225" ref-type="bibr">88</xref>]. Copyright 2024, Mater. Elsevier Ltd. (<bold>c</bold>) Schematic illustration of the synthetic and antitumor immune potency of aluminum-integrated antigen-MOF (ZANPs). Reproduced with permission [<xref rid="B96-pharmaceutics-17-00225" ref-type="bibr">96</xref>]. Copyright 2019, Elsevier B.V. (<bold>d</bold>) Schematic illustration of the synthetic route and therapeutic mechanism of NMCAH. Reproduced with permission [<xref rid="B99-pharmaceutics-17-00225" ref-type="bibr">99</xref>]. Copyright 2024, Elsevier Ltd.</p></caption><graphic xlink:href="pharmaceutics-17-00225-g006" position="float"/></fig><p>The key to tumor vaccines for immunotherapy is to ensure the activation of the whole process. The employment of MOFs as vectors for tumor vaccines help increase the antigen levels, improve the antigen presentation efficacy, lead to refined vaccine efficiency, and promote DC maturation and CTL activation, and help reshape the TIME.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceutics-17-00225"><title>4. Conclusions and Prospects</title><p>In summary, MOFs have emerged as outstanding candidates for drug delivery systems in recent years, garnering significant interest in tumor immunotherapy. By combining the high safety of organic carriers with the high drug-loading capacity of inorganic carriers, MOFs have benefits such as high porosity, substantial drug-loading capacity, and adjustable structures, as well as responsiveness to optical, acoustic, and pH stimuli. Since MOFs inherently release metal ions, they have the ability to activate tumor immunity. However, the superior immune activation properties of MOFs act as a &#x0201c;double-edged sword&#x0201d;. Cell cytotoxicity, along with its immunity activation ability, reduces the concentration threshold required for application. In order to improve the biocompatibility of MOFs, researchers have conducted various surface modifications on MOFs, such as PEGylation and cell membrane encapsulation. These methods not only improve their biocompatibility, but also endow them with special functionalities, such as tumor targeting, improved solubility, and increased cellular uptake. These advancements are crucial for promoting the clinical application of MOFs and will likely be a focal point of future research endeavors.</p><p>In this review, the classification and advantages of MOFs as delivery vectors are introduced. Subsequently, the research progress of antitumor immunotherapy systems based on MOFs is discussed, in accordance with the immunity activation mechanisms of agents loaded in MOFs. A concise overview of MOF-based delivery systems for antitumor immunotherapy introduced in this review is summarized in <xref rid="pharmaceutics-17-00225-t001" ref-type="table">Table 1</xref>. Based on their ability to activate antitumor immunity, MOFs and their loaded agents have synergistic effects in tumor treatment. Herein, delivery systems based on MOFs have been comprehensively utilized for small-molecule drugs, therapeutic antibodies, and nucleic acid-based therapeutics. Their applications for other novel agents, such as gene editors or CAR-T cells, need pioneering investigation. Hopefully, this review can help provide new insights for future studies on MOFs and help promote their clinical applications. </p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>All authors contributed to the article&#x02019;s preparation. Conceptualization, N.Y. and T.L.; visualization, N.Y. and Z.H.; supervision, T.L.; writing&#x02014;original draft, N.Y.; writing&#x02014;review and editing, N.Y., Z.H. and T.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00225"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bray</surname><given-names>F.</given-names></name>
<name><surname>Laversanne</surname><given-names>M.</given-names></name>
<name><surname>Sung</surname><given-names>H.</given-names></name>
<name><surname>Ferlay</surname><given-names>J.</given-names></name>
<name><surname>Siegel</surname><given-names>R.L.</given-names></name>
<name><surname>Soerjomataram</surname><given-names>I.</given-names></name>
<name><surname>Jemal</surname><given-names>A.</given-names></name>
</person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J. Clin.</source><year>2024</year><volume>74</volume><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00225"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>X.F.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
</person-group><article-title>Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy</article-title><source>Acta Pharmacol. Sin.</source><year>2020</year><volume>4</volume><fpage>1928</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-0414-6</pub-id><pub-id pub-id-type="pmid">32355277</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00225"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Tiruthani</surname><given-names>K.</given-names></name>
</person-group><article-title>Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer</article-title><source>Nanomedicine</source><year>2019</year><volume>21</volume><fpage>102034</fpage><pub-id pub-id-type="doi">10.1016/j.nano.2019.102034</pub-id><pub-id pub-id-type="pmid">31207314</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00225"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
</person-group><article-title>The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications</article-title><source>Cell. Mol. Immunol.</source><year>2020</year><volume>17</volume><fpage>807</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0488-6</pub-id><pub-id pub-id-type="pmid">32612154</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00225"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yaremenko</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>M.M.</given-names></name>
<name><surname>Zhen</surname><given-names>X.Y.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Tao</surname><given-names>W.</given-names></name>
</person-group><article-title>Clinical advances of mRNA vaccines for cancer immunotherapy</article-title><source>Med</source><year>2025</year><volume>6</volume><fpage>2666</fpage><lpage>6340</lpage><pub-id pub-id-type="doi">10.1016/j.medj.2024.11.015</pub-id><pub-id pub-id-type="pmid">39798545</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00225"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Visser</surname><given-names>K.</given-names></name>
<name><surname>Joyce</surname><given-names>J.A.</given-names></name>
</person-group><article-title>The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><fpage>374</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.02.016</pub-id><pub-id pub-id-type="pmid">36917948</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00225"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arner</surname><given-names>E.N.</given-names></name>
<name><surname>Rathmell</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Metabolic programming and immune suppression in the tumor microenvironment</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.01.009</pub-id><pub-id pub-id-type="pmid">36801000</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00225"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>D.S.</given-names></name>
<name><surname>Mellman</surname><given-names>I.</given-names></name>
</person-group><article-title>Oncology meets immunology: The cancer-immunity cycle</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.012</pub-id><pub-id pub-id-type="pmid">23890059</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00225"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bear</surname><given-names>A.S.</given-names></name>
<name><surname>Vonderheide</surname><given-names>R.H.</given-names></name>
<name><surname>Hara</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Challenges and Opportunities for Pancreatic Cancer Immunotherapy</article-title><source>Cancer Cell</source><year>2020</year><volume>38</volume><fpage>788</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.08.004</pub-id><pub-id pub-id-type="pmid">32946773</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00225"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haynes</surname><given-names>N.M.</given-names></name>
<name><surname>Chadwick</surname><given-names>T.B.</given-names></name>
<name><surname>Parker</surname><given-names>B.S.</given-names></name>
</person-group><article-title>The complexity of immune evasion mechanisms throughout the metastatic cascade</article-title><source>Nat. Immunol.</source><year>2024</year><volume>25</volume><fpage>1793</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1038/s41590-024-01960-4</pub-id><pub-id pub-id-type="pmid">39285252</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00225"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Wen</surname><given-names>H.</given-names></name>
<name><surname>Cui</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>W.</given-names></name>
<name><surname>Qian</surname><given-names>G.</given-names></name>
<name><surname>Chen</surname><given-names>B.</given-names></name>
</person-group><article-title>Emerging multifunctional metal&#x02013;organic framework materials</article-title><source>Adv. Mater.</source><year>2016</year><volume>28</volume><fpage>8819</fpage><lpage>8860</lpage><pub-id pub-id-type="doi">10.1002/adma.201601133</pub-id><pub-id pub-id-type="pmid">27454668</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00225"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pereira</surname><given-names>R.F.</given-names></name>
<name><surname>Pinto</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Metal-organic frameworks applications in synergistic cancer photo-immunotherapy</article-title><source>Polymers</source><year>2023</year><volume>15</volume><elocation-id>1490</elocation-id><pub-id pub-id-type="doi">10.3390/polym15061490</pub-id><pub-id pub-id-type="pmid">36987269</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00225"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ni</surname><given-names>W.D.</given-names></name>
<name><surname>Wu</surname><given-names>J.Y.</given-names></name>
<name><surname>Fang</surname><given-names>H.P.</given-names></name>
<name><surname>Feng</surname><given-names>Y.J.</given-names></name>
<name><surname>Hu</surname><given-names>Y.Y.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>F.F.</given-names></name>
<name><surname>Tian</surname><given-names>H.Y.</given-names></name>
</person-group><article-title>Photothermal-Chemotherapy Enhancing Tumor Immunotherapy by Multifunctional Metal&#x02013;Organic Framework Based Drug Delivery System</article-title><source>Nano Lett.</source><year>2021</year><volume>21</volume><fpage>7796</fpage><lpage>7805</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.1c02782</pub-id><pub-id pub-id-type="pmid">34516141</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00225"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>M.R.</given-names></name>
<name><surname>Chen</surname><given-names>G.S.</given-names></name>
<name><surname>Qin</surname><given-names>L.Y.</given-names></name>
<name><surname>Qu</surname><given-names>C.H.</given-names></name>
<name><surname>Dong</surname><given-names>X.X.</given-names></name>
<name><surname>Ni</surname><given-names>J.</given-names></name>
<name><surname>Yin</surname><given-names>X.B.</given-names></name>
</person-group><article-title>Metal Organic Frameworks as Drug Targeting Delivery Vehicles in the Treatment of Cancer</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>232</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12030232</pub-id><pub-id pub-id-type="pmid">32151012</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00225"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rieter</surname><given-names>J.W.</given-names></name>
<name><surname>Taylor</surname><given-names>M.L.K.</given-names></name>
<name><surname>An</surname><given-names>H.</given-names></name>
<name><surname>Lin</surname><given-names>W.</given-names></name>
<name><surname>Lin</surname><given-names>W.</given-names></name>
</person-group><article-title>Nanoscale metal organic frameworks as potential multimodal contrast enhancing agents</article-title><source>J. Am. Chem. Soc.</source><year>2006</year><volume>128</volume><fpage>9024</fpage><lpage>9025</lpage><pub-id pub-id-type="doi">10.1021/ja0627444</pub-id><pub-id pub-id-type="pmid">16834362</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00225"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>K.</given-names></name>
<name><surname>Aung</surname><given-names>T.</given-names></name>
<name><surname>Guo</surname><given-names>N.</given-names></name>
<name><surname>Weichselbaum</surname><given-names>R.</given-names></name>
<name><surname>Lin</surname><given-names>W.</given-names></name>
</person-group><article-title>Nanoscale metal&#x02013;organic frameworks for therapeutic, imaging, and sensing applications</article-title><source>Adv. Mater.</source><year>2018</year><volume>30</volume><fpage>1707634</fpage><pub-id pub-id-type="doi">10.1002/adma.201707634</pub-id></element-citation></ref><ref id="B17-pharmaceutics-17-00225"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Furukawa</surname><given-names>H.</given-names></name>
<name><surname>Cordova</surname><given-names>K.E.</given-names></name>
<name><surname>O&#x02019;Keeffe</surname><given-names>M.</given-names></name>
<name><surname>Yaghi</surname><given-names>O.M.</given-names></name>
</person-group><article-title>The chemistry and applications of metal-organic frameworks</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>123044</fpage><pub-id pub-id-type="doi">10.1126/science.1230444</pub-id><pub-id pub-id-type="pmid">23990564</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00225"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Long</surname><given-names>J.R.</given-names></name>
<name><surname>Yaghi</surname><given-names>O.M.</given-names></name>
</person-group><article-title>Introduction to metal&#x02013;organic frameworks</article-title><source>Chem. Rev.</source><year>2012</year><volume>112</volume><fpage>673</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1021/cr300014x</pub-id><pub-id pub-id-type="pmid">22280456</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00225"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patricia</surname><given-names>H.</given-names></name>
<name><surname>Serre</surname><given-names>C.</given-names></name>
<name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name>
<name><surname>Sebban</surname><given-names>M.</given-names></name>
<name><surname>Taulelle</surname><given-names>F.</given-names></name>
<name><surname>F&#x000e9;rey</surname><given-names>G.</given-names></name>
</person-group><article-title>Metal&#x02013;organic frameworks as efficient materials for drug delivery</article-title><source>Angew. Chem. Int. Ed.</source><year>2006</year><volume>45</volume><fpage>5974</fpage><lpage>5978</lpage><pub-id pub-id-type="doi">10.1002/anie.200601878</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-00225"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gim&#x000e9;nez-Marqu&#x000e9;s</surname><given-names>M.</given-names></name>
<name><surname>Bellido</surname><given-names>E.</given-names></name>
<name><surname>Berthelot</surname><given-names>T.</given-names></name>
<name><surname>Sim&#x000f3;n-Yarza</surname><given-names>T.</given-names></name>
<name><surname>Hidalgo</surname><given-names>T.</given-names></name>
<name><surname>Sim&#x000f3;n-V&#x000e1;zquez</surname><given-names>R.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Fern&#x000e1;ndez</surname><given-names>&#x000c1;.</given-names></name>
<name><surname>Avila</surname><given-names>J.</given-names></name>
<name><surname>Asensio</surname><given-names>M.C.</given-names></name>
<name><surname>Gref</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Graftfast surface engineering to improve mof nanoparticles furtiveness</article-title><source>Small</source><year>2018</year><volume>14</volume><fpage>1801900</fpage><pub-id pub-id-type="doi">10.1002/smll.201801900</pub-id><pub-id pub-id-type="pmid">30091524</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00225"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Gong</surname><given-names>T.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
</person-group><article-title>Recent advancement of imidazolate framework (ZIF-8) based nanoformulations for synergistic tumor therapy</article-title><source>Nnanoscale</source><year>2019</year><volume>11</volume><fpage>21030</fpage><lpage>21045</lpage><pub-id pub-id-type="doi">10.1039/C9NR06558J</pub-id><pub-id pub-id-type="pmid">31674617</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00225"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Bi</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>R.</given-names></name>
<name><surname>He</surname><given-names>F.</given-names></name>
<name><surname>Gai</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Hyaluronic acid-targeted and pH-responsive drug delivery system based on metal-organic frameworks for efficient antitumor Therapy</article-title><source>Biomaterials</source><year>2019</year><volume>223</volume><elocation-id>119473</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119473</pub-id><pub-id pub-id-type="pmid">31499255</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00225"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>A.</given-names></name>
<name><surname>Jing</surname><given-names>W.</given-names></name>
<name><surname>Sun</surname><given-names>P.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Du</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection</article-title><source>Nat. Nanotechnol.</source><year>2021</year><volume>16</volume><fpage>538</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-00843-7</pub-id><pub-id pub-id-type="pmid">33526838</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00225"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Jiang</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Luan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Rational design of metal organic framework nanocarrier-based codelivery system of doxorubicin hydrochloride/verapamil hydrochloride for overcoming multidrug resistance with efficient targeted cancer therapy</article-title><source>ACS Appl. Mater. Interfaces</source><year>2017</year><volume>9</volume><fpage>19687</fpage><lpage>19697</lpage><pub-id pub-id-type="doi">10.1021/acsami.7b05142</pub-id><pub-id pub-id-type="pmid">28530401</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00225"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>M.</given-names></name>
<name><surname>Zeng</surname><given-names>W.</given-names></name>
<name><surname>Ouyang</surname><given-names>Y.</given-names></name>
<name><surname>Liang</surname><given-names>S.</given-names></name>
<name><surname>Yi</surname><given-names>Y.</given-names></name>
<name><surname>Hao</surname><given-names>H.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Nie</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>ATP-exhausted nanocomplexes for intratumoral metabolic intervention and photoimmunotherapy</article-title><source>Biomaterials</source><year>2022</year><volume>284</volume><elocation-id>121503</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121503</pub-id><pub-id pub-id-type="pmid">35367841</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00225"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>F.</given-names></name>
<name><surname>Jia</surname><given-names>J.</given-names></name>
<name><surname>He</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>A.</given-names></name>
<name><surname>Zhu</surname><given-names>G.</given-names></name>
</person-group><article-title>A highly porous medical metal&#x02013;organic framework constructed from bioactive curcumin</article-title><source>Chem. Commun.</source><year>2015</year><volume>51</volume><fpage>5774</fpage><lpage>5777</lpage><pub-id pub-id-type="doi">10.1039/C4CC10159F</pub-id><pub-id pub-id-type="pmid">25722997</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00225"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grall</surname><given-names>R.</given-names></name>
<name><surname>Hidalgo</surname><given-names>T.</given-names></name>
<name><surname>Delic</surname><given-names>J.</given-names></name>
<name><surname>Garcia-Marquez</surname><given-names>A.</given-names></name>
<name><surname>Chevillard</surname><given-names>S.</given-names></name>
<name><surname>Horcajada</surname><given-names>P.</given-names></name>
</person-group><article-title><italic toggle="yes">In vitro</italic> biocompatibility of mesoporous metal (III.; Fe, Al, Cr) trimesate MOF nanocarriers</article-title><source>J. Mater. Chem. B</source><year>2015</year><volume>3</volume><fpage>8279</fpage><lpage>8292</lpage><pub-id pub-id-type="doi">10.1039/C5TB01223F</pub-id><pub-id pub-id-type="pmid">32262883</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00225"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tabar</surname><given-names>C.T.</given-names></name>
<name><surname>Cunha</surname><given-names>D.</given-names></name>
<name><surname>Imbuluzqueta</surname><given-names>E.</given-names></name>
<name><surname>Ragon</surname><given-names>F.</given-names></name>
<name><surname>Serre</surname><given-names>C.</given-names></name>
<name><surname>Prieto</surname><given-names>M.J.</given-names></name>
<name><surname>Horcajada</surname><given-names>P.</given-names></name>
</person-group><article-title>Cytotoxicity of nanoscaled metal&#x02013;organic frameworks</article-title><source>J. Mater. Chem. B</source><year>2014</year><volume>2</volume><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1039/C3TB20832J</pub-id><pub-id pub-id-type="pmid">32261505</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00225"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horcajada</surname><given-names>P.</given-names></name>
<name><surname>Chalati</surname><given-names>T.</given-names></name>
<name><surname>Serre</surname><given-names>C.</given-names></name>
<name><surname>Gillet</surname><given-names>B.</given-names></name>
<name><surname>Sebrie</surname><given-names>C.</given-names></name>
<name><surname>Baati</surname><given-names>T.</given-names></name>
<name><surname>Eubank</surname><given-names>J.F.</given-names></name>
<name><surname>Heurtaux</surname><given-names>D.</given-names></name>
<name><surname>Clayette</surname><given-names>P.</given-names></name>
<name><surname>Kreuz</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Porous metal&#x02013;organic-framework nanoscale carriers as a potential platform for drug delivery and imaging</article-title><source>Nat. Mater.</source><year>2010</year><volume>9</volume><fpage>172</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1038/nmat2608</pub-id><pub-id pub-id-type="pmid">20010827</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00225"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Yao</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>F.Q.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Duan</surname><given-names>W.Y.</given-names></name>
<name><surname>Tian</surname><given-names>Y.P.</given-names></name>
<name><surname>Li</surname><given-names>D.D.</given-names></name>
</person-group><article-title>A tumor microenvironment-activated metal-organic framework&#x02013;based nanoplatform for amplified oxidative stress&#x02013;induced enhanced chemotherapy</article-title><source>J. Biol. Chem.</source><year>2023</year><volume>299</volume><elocation-id>102742</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2022.102742</pub-id><pub-id pub-id-type="pmid">36435198</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00225"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hua</surname><given-names>Y.</given-names></name>
<name><surname>Qin</surname><given-names>M.T.</given-names></name>
<name><surname>Lu</surname><given-names>S.Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.X.</given-names></name>
<name><surname>Tan</surname><given-names>S.T.</given-names></name>
<name><surname>Ding</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
</person-group><article-title>Hyaluronic acid-functionalized MOFs for combined sunitinib and siRNA therapy in renal cell carcinoma</article-title><source>Int. J. Biol. Macromol.</source><year>2024</year><volume>283</volume><elocation-id>137317</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.137317</pub-id><pub-id pub-id-type="pmid">39510472</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00225"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cunha</surname><given-names>D.</given-names></name>
<name><surname>Yahia</surname><given-names>M.B.</given-names></name>
<name><surname>Hall</surname><given-names>S.</given-names></name>
<name><surname>Miller</surname><given-names>S.R.</given-names></name>
<name><surname>Chevreau</surname><given-names>H.</given-names></name>
<name><surname>Elkaim</surname><given-names>E.</given-names></name>
<name><surname>Maurin</surname><given-names>G.</given-names></name>
<name><surname>Horcajada</surname><given-names>P.</given-names></name>
<name><surname>Serre</surname><given-names>C.</given-names></name>
</person-group><article-title>Rationale of drug encapsulation and release from biocompatible porous metal&#x02013;organic frameworks</article-title><source>Chem. Mater.</source><year>2013</year><volume>25</volume><fpage>2767</fpage><lpage>2776</lpage><pub-id pub-id-type="doi">10.1021/cm400798p</pub-id></element-citation></ref><ref id="B33-pharmaceutics-17-00225"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Y.J.</given-names></name>
<name><surname>Zheng</surname><given-names>L.W.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Qian</surname><given-names>X.</given-names></name>
<name><surname>Fu</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>X.W.</given-names></name>
<name><surname>Yang</surname><given-names>Z.Y.</given-names></name>
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Cui</surname><given-names>C.</given-names></name>
<name><surname>Tan</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Metal&#x02013;organic framework nanocarriers for drug delivery in biomedical applications</article-title><source>Nano-Micro Lett.</source><year>2020</year><volume>12</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1007/s40820-020-00423-3</pub-id><pub-id pub-id-type="pmid">34138099</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00225"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Du</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Tao</surname><given-names>Y.</given-names></name>
<name><surname>Ren</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Qin</surname><given-names>H.</given-names></name>
</person-group><article-title>Disrupting intracellular iron homeostasis by engineered metal-organic framework for nanocatalytic tumor therapy in synergy with autophagy amplification-promoted ferroptosis</article-title><source>Adv. Funct. Mater.</source><year>2023</year><volume>33</volume><fpage>2215244</fpage><pub-id pub-id-type="doi">10.1002/adfm.202215244</pub-id></element-citation></ref><ref id="B35-pharmaceutics-17-00225"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ploetz</surname><given-names>E.</given-names></name>
<name><surname>Zimpel</surname><given-names>A.</given-names></name>
<name><surname>Cauda</surname><given-names>V.</given-names></name>
<name><surname>Bauer</surname><given-names>D.</given-names></name>
<name><surname>Lamb</surname><given-names>D.C.</given-names></name>
<name><surname>Haisch</surname><given-names>C.</given-names></name>
<name><surname>Zahler</surname><given-names>S.</given-names></name>
<name><surname>Vollmar</surname><given-names>A.M.</given-names></name>
<name><surname>Wuttke</surname><given-names>S.</given-names></name>
<name><surname>Engelke</surname><given-names>H.</given-names></name>
</person-group><article-title>Metal&#x02013;organic framework nanoparticles induce pyroptosis in cells controlled by the extracellular pH</article-title><source>Adv. Mater.</source><year>2020</year><volume>32</volume><fpage>1907267</fpage><pub-id pub-id-type="doi">10.1002/adma.201907267</pub-id></element-citation></ref><ref id="B36-pharmaceutics-17-00225"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Cao</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
</person-group><article-title>PEGylated Mn containing MOF nanoparticles for potential immunotherapy of pancreatic cancer via manganese induced activation of anti-tumor immunity</article-title><source>Colloid Interface Sci. Commun.</source><year>2021</year><volume>42</volume><fpage>100409</fpage><pub-id pub-id-type="doi">10.1016/j.colcom.2021.100409</pub-id></element-citation></ref><ref id="B37-pharmaceutics-17-00225"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Tan</surname><given-names>J.</given-names></name>
<name><surname>Meng</surname><given-names>Q.</given-names></name>
<name><surname>Zheng</surname><given-names>P.</given-names></name>
<name><surname>Ma</surname><given-names>P.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
</person-group><article-title>ZIF-8 nanoparticles evoke pyroptosis for high-efficiency cancer immunotherapy</article-title><source>Angew. Chem. Int. Ed.</source><year>2023</year><volume>62</volume><fpage>e202215307</fpage><pub-id pub-id-type="doi">10.1002/anie.202215307</pub-id><pub-id pub-id-type="pmid">36629270</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00225"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Zhen</surname><given-names>X.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
</person-group><article-title>Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy</article-title><source>Biomaterials</source><year>2022</year><volume>280</volume><elocation-id>121261</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121261</pub-id><pub-id pub-id-type="pmid">34815099</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00225"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Ren</surname><given-names>Y.</given-names></name>
<name><surname>Su</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Yu</surname><given-names>D.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Chao</surname><given-names>M.</given-names></name>
<name><surname>Wu</surname><given-names>G.</given-names></name>
<name><surname>Jiang</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>A dual-pathway pyroptosis inducer based on Au&#x02013;Cu2-xse@ZIF-8 enhances tumor immunotherapy by disrupting the zinc ion homeostasis</article-title><source>Acta Biomater.</source><year>2024</year><volume>188</volume><fpage>329</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2024.09.015</pub-id><pub-id pub-id-type="pmid">39278301</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00225"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Shim</surname><given-names>M.K.</given-names></name>
<name><surname>Kim</surname><given-names>W.J.</given-names></name>
<name><surname>Choi</surname><given-names>J.</given-names></name>
<name><surname>Nam</surname><given-names>G.-H.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Moon</surname><given-names>Y.</given-names></name>
<name><surname>Kim</surname><given-names>H.Y.</given-names></name>
<name><surname>Park</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity</article-title><source>Biomaterials</source><year>2021</year><volume>272</volume><elocation-id>120791</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120791</pub-id><pub-id pub-id-type="pmid">33831739</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00225"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>X.</given-names></name>
<name><surname>Bian</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
</person-group><article-title>Induction of immunogenic cell death by novel platinum-based anticancer agents</article-title><source>Pharmacol. Res.</source><year>2023</year><volume>187</volume><fpage>106556</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2022.106556</pub-id><pub-id pub-id-type="pmid">36403722</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00225"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lau</surname><given-names>T.S.</given-names></name>
<name><surname>Chan</surname><given-names>L.K.Y.</given-names></name>
<name><surname>Man</surname><given-names>G.C.W.</given-names></name>
<name><surname>Wong</surname><given-names>C.H.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.S.</given-names></name>
<name><surname>Yim</surname><given-names>S.F.</given-names></name>
<name><surname>Cheung</surname><given-names>T.H.</given-names></name>
<name><surname>McNeish</surname><given-names>I.A.</given-names></name>
<name><surname>Kwong</surname><given-names>J.</given-names></name>
</person-group><article-title>Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis</article-title><source>Cancer Immunol. Res.</source><year>2020</year><volume>8</volume><fpage>1099</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-19-0616</pub-id><pub-id pub-id-type="pmid">32354736</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00225"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Ji</surname><given-names>J.</given-names></name>
<name><surname>Xi</surname><given-names>Y.</given-names></name>
<name><surname>Ye</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Intelligent self-amplifying ferroptosis-inducible nanoplatform for enhanced tumor microenvironment reconstruction and combination therapy</article-title><source>Chem. Eng. J.</source><year>2023</year><volume>468</volume><fpage>143729</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2023.143729</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-00225"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Cao</surname><given-names>Y.</given-names></name>
<name><surname>Bai</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Song</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Triple-pathway cGAS-STING activation collaborated with ferroptosis-induced immunogenic cell death for boosting systemic colorectal cancer immunotherapy</article-title><source>Nano Today</source><year>2024</year><volume>59</volume><fpage>102484</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2024.102484</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-00225"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Ming</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>T.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
<name><surname>Du</surname><given-names>Z.</given-names></name>
</person-group><article-title>A pH and glutathione-responsive carbon monoxide-driven nano-herb delivery system for enhanced immunotherapy in colorectal cancer</article-title><source>J. Control. Release</source><year>2024</year><volume>376</volume><fpage>659</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.10.043</pub-id><pub-id pub-id-type="pmid">39442888</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00225"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>M.</given-names></name>
<name><surname>Qi</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><article-title>The Caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer</article-title><source>Cell Death Discov.</source><year>2020</year><volume>6</volume><fpage>112</fpage><pub-id pub-id-type="doi">10.1038/s41420-020-00349-0</pub-id><pub-id pub-id-type="pmid">33133646</pub-id>
</element-citation></ref><ref id="B47-pharmaceutics-17-00225"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>S.</given-names></name>
<name><surname>Shang</surname><given-names>Q.</given-names></name>
<name><surname>Ji</surname><given-names>J.</given-names></name>
<name><surname>Luan</surname><given-names>Y.</given-names></name>
</person-group><article-title>A nanoplatform to amplify apoptosis-to-pyroptosis immunotherapy via immunomodulation of myeloid-derived suppressor cells</article-title><source>ACS Appl. Mater. Interfaces</source><year>2021</year><volume>13</volume><fpage>47407</fpage><lpage>47417</lpage><pub-id pub-id-type="doi">10.1021/acsami.1c16154</pub-id><pub-id pub-id-type="pmid">34597015</pub-id>
</element-citation></ref><ref id="B48-pharmaceutics-17-00225"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Jin</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Quan</surname><given-names>X.</given-names></name>
<name><surname>Jin</surname><given-names>M.</given-names></name>
<name><surname>Gao</surname><given-names>Z.</given-names></name>
<name><surname>Jin</surname><given-names>Y.</given-names></name>
</person-group><article-title>A self-targeting MOFs nanoplatform for treating metastatic triple-negative breast cancer through tumor microenvironment remodeling and chemotherapy potentiation</article-title><source>Int. J. Pharm.</source><year>2024</year><volume>664</volume><fpage>124625</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.124625</pub-id><pub-id pub-id-type="pmid">39182743</pub-id>
</element-citation></ref><ref id="B49-pharmaceutics-17-00225"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Zhu</surname><given-names>B.</given-names></name>
<name><surname>Deng</surname><given-names>W.</given-names></name>
<name><surname>Ye</surname><given-names>Q.</given-names></name>
<name><surname>Bai</surname><given-names>B.</given-names></name>
<name><surname>Liang</surname><given-names>D.</given-names></name>
<name><surname>Shao</surname><given-names>B.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Engineering metal-organic framework nanoparticles trigger pyroptosis to boost colon cancer immunotherapy</article-title><source>Mater. Des.</source><year>2024</year><volume>238</volume><fpage>112731</fpage><pub-id pub-id-type="doi">10.1016/j.matdes.2024.112731</pub-id></element-citation></ref><ref id="B50-pharmaceutics-17-00225"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xing</surname><given-names>G.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Sheng</surname><given-names>S.</given-names></name>
<name><surname>Jin</surname><given-names>L.</given-names></name>
<name><surname>Zhu</surname><given-names>D.</given-names></name>
<name><surname>Mei</surname><given-names>L.</given-names></name>
<name><surname>Dong</surname><given-names>X.</given-names></name>
<name><surname>Lv</surname><given-names>F.</given-names></name>
</person-group><article-title>Macrophages-based biohybrid microrobots for breast cancer photothermal immunotherapy by inducing pyroptosis</article-title><source>Small</source><year>2023</year><volume>20</volume><fpage>2305526</fpage><pub-id pub-id-type="doi">10.1002/smll.202305526</pub-id></element-citation></ref><ref id="B51-pharmaceutics-17-00225"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Han</surname><given-names>M.</given-names></name>
<name><surname>Yan</surname><given-names>F.</given-names></name>
<name><surname>Shi</surname><given-names>Z.</given-names></name>
<name><surname>Feng</surname><given-names>S.</given-names></name>
</person-group><article-title>Ultrasound-triggered O2 bombs: Perfluorobromooctane-loaded defect-rich metal-organic framework for enhanced sono-immunotherapy</article-title><source>Chem. Eng. J.</source><year>2023</year><volume>474</volume><fpage>145764</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2023.145764</pub-id></element-citation></ref><ref id="B52-pharmaceutics-17-00225"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>A.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Lin</surname><given-names>H.</given-names></name>
<name><surname>Liao</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Mao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Harnessing innate immune pathways for therapeutic advancement in cancer</article-title><source>Signal Transduct. Target. Ther.</source><year>2024</year><volume>9</volume><fpage>68</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01765-9</pub-id><pub-id pub-id-type="pmid">38523155</pub-id>
</element-citation></ref><ref id="B53-pharmaceutics-17-00225"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Demaria</surname><given-names>O.</given-names></name>
<name><surname>Cornen</surname><given-names>S.</given-names></name>
<name><surname>Da&#x000eb;ron</surname><given-names>M.</given-names></name>
<name><surname>Morel</surname><given-names>Y.</given-names></name>
<name><surname>Medzhitov</surname><given-names>R.</given-names></name>
<name><surname>Vivier</surname><given-names>E.</given-names></name>
</person-group><article-title>Harnessing innate immunity in cancer therapy</article-title><source>Nature</source><year>2019</year><volume>574</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1593-5</pub-id><pub-id pub-id-type="pmid">31578484</pub-id>
</element-citation></ref><ref id="B54-pharmaceutics-17-00225"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>Z.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Zhong</surname><given-names>M.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Mai</surname><given-names>Z.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Ma</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>An acid-responsive mof nanomedicine for augmented anti-tumor immunotherapy via a metal ion interference-mediated pyroptotic pathway</article-title><source>Biomaterials</source><year>2023</year><volume>302</volume><elocation-id>122333</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2023.122333</pub-id><pub-id pub-id-type="pmid">37738743</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00225"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Hao</surname><given-names>Q.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>R.</given-names></name>
<name><surname>Feng</surname><given-names>L.</given-names></name>
<name><surname>He</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>He</surname><given-names>G.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Yang</surname><given-names>P.</given-names></name>
</person-group><article-title>Thermoelectric nanoheterojunction-mediated multiple energy conversion for enhanced cancer therapy</article-title><source>ACS Nano</source><year>2024</year><volume>18</volume><fpage>34257</fpage><lpage>34271</lpage><pub-id pub-id-type="doi">10.1021/acsnano.4c12261</pub-id><pub-id pub-id-type="pmid">39630424</pub-id>
</element-citation></ref><ref id="B56-pharmaceutics-17-00225"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Xu</surname><given-names>P.</given-names></name>
</person-group><article-title>Cellular functions of cGAS-STING signaling</article-title><source>Trends Cell Biol.</source><year>2023</year><volume>33</volume><fpage>630</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2022.11.001</pub-id><pub-id pub-id-type="pmid">36437149</pub-id>
</element-citation></ref><ref id="B57-pharmaceutics-17-00225"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>T.</given-names></name>
<name><surname>Jiang</surname><given-names>X.</given-names></name>
<name><surname>Fan</surname><given-names>Y.</given-names></name>
<name><surname>Yuan</surname><given-names>E.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Tillman</surname><given-names>L.</given-names></name>
<name><surname>Lin</surname><given-names>W.</given-names></name>
</person-group><article-title>STING agonist-conjugated metal-organic framework induces artificial leukocytoid structures and immune hotspots for systemic antitumor responses</article-title><source>Natl. Sci. Rev.</source><year>2024</year><volume>11</volume><fpage>nwae167</fpage><pub-id pub-id-type="doi">10.1093/nsr/nwae167</pub-id><pub-id pub-id-type="pmid">38887543</pub-id>
</element-citation></ref><ref id="B58-pharmaceutics-17-00225"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>G.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>R.</given-names></name>
<name><surname>Xu</surname><given-names>B.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Han</surname><given-names>X.</given-names></name>
<name><surname>Shao</surname><given-names>T.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Spiky metal-organic framework nanosystem for enhanced cuproptosis-mediated cancer immunotherapy</article-title><source>Nano Today</source><year>2024</year><volume>56</volume><fpage>102231</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2024.102231</pub-id></element-citation></ref><ref id="B59-pharmaceutics-17-00225"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Du</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Pu</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>A DNA/DMXAA/metal&#x02013;organic framework activator of innate immunity for boosting anticancer immunity</article-title><source>Adv. Mater.</source><year>2023</year><volume>35</volume><fpage>2210440</fpage><pub-id pub-id-type="doi">10.1002/adma.202210440</pub-id><pub-id pub-id-type="pmid">36656162</pub-id>
</element-citation></ref><ref id="B60-pharmaceutics-17-00225"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castelo-Soccio</surname><given-names>L.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Gadina</surname><given-names>M.</given-names></name>
<name><surname>Schwartzberg</surname><given-names>P.L.</given-names></name>
<name><surname>Laurence</surname><given-names>A.</given-names></name>
<name><surname>O&#x02019;Shea</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Protein kinases: Drug targets for immunological disorders</article-title><source>Nat. Rev. Immunol.</source><year>2023</year><volume>23</volume><fpage>787</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1038/s41577-023-00877-7</pub-id><pub-id pub-id-type="pmid">37188939</pub-id>
</element-citation></ref><ref id="B61-pharmaceutics-17-00225"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Zhong</surname><given-names>D.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Duan</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Niu</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy</article-title><source>Biomaterials</source><year>2024</year><volume>311</volume><elocation-id>122695</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2024.122695</pub-id><pub-id pub-id-type="pmid">38954960</pub-id>
</element-citation></ref><ref id="B62-pharmaceutics-17-00225"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Zhong</surname><given-names>H.</given-names></name>
</person-group><article-title>Lenvatinib delivery using a Gd/Fe bimetallic MOF enhancing antitumor immunity following microwave-based thermal therapy</article-title><source>Acta Biomater.</source><year>2023</year><volume>172</volume><fpage>382</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2023.09.052</pub-id><pub-id pub-id-type="pmid">37797707</pub-id>
</element-citation></ref><ref id="B63-pharmaceutics-17-00225"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morad</surname><given-names>G.</given-names></name>
<name><surname>Helmink</surname><given-names>B.A.</given-names></name>
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>Wargo</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Hallmarks of response, resistance, and toxicity to immune checkpoint blockade</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>5309</fpage><lpage>5337</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.09.020</pub-id><pub-id pub-id-type="pmid">34624224</pub-id>
</element-citation></ref><ref id="B64-pharmaceutics-17-00225"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>Goswami</surname><given-names>S.</given-names></name>
<name><surname>Raychaudhuri</surname><given-names>D.</given-names></name>
<name><surname>Siddiqui</surname><given-names>B.A.</given-names></name>
<name><surname>Singh</surname><given-names>P.</given-names></name>
<name><surname>Nagarajan</surname><given-names>A.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Subudhi</surname><given-names>S.K.</given-names></name>
<name><surname>Poon</surname><given-names>C.</given-names></name>
<name><surname>Gant</surname><given-names>K.L.</given-names></name>
<etal/>
</person-group><article-title>Immune checkpoint therapy&#x02014;Current perspectives and future directions</article-title><source>Cell</source><year>2023</year><volume>186</volume><fpage>1652</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.03.006</pub-id><pub-id pub-id-type="pmid">37059068</pub-id>
</element-citation></ref><ref id="B65-pharmaceutics-17-00225"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Wu</surname><given-names>Q.</given-names></name>
<name><surname>You</surname><given-names>Y.</given-names></name>
<name><surname>Lan</surname><given-names>Z.</given-names></name>
<name><surname>Zou</surname><given-names>K.-L.</given-names></name>
<name><surname>Cheng</surname><given-names>G.-W.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Han</surname><given-names>Y.-H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Microwave-responsive gadolinium metal-organic frameworks nanosystem for MRI-guided cancer thermotherapy and synergistic immunotherapy</article-title><source>Bioact. Mater.</source><year>2024</year><volume>33</volume><fpage>532</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2023.11.010</pub-id><pub-id pub-id-type="pmid">38162511</pub-id>
</element-citation></ref><ref id="B66-pharmaceutics-17-00225"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bertrand</surname><given-names>P.</given-names></name>
</person-group><article-title>Aptamers targeting the PD-1/PD-L1 axis: A perspective</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><fpage>10878</fpage><lpage>10888</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c00551</pub-id><pub-id pub-id-type="pmid">37561598</pub-id>
</element-citation></ref><ref id="B67-pharmaceutics-17-00225"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Cao</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Fan</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
</person-group><article-title>Core-shell nanomedicine based on multifunctional tetrahedral DNA nanostructures for synergistic enhancement of tumor chemodynamic/chemo-immunotherapy</article-title><source>Chem. Eng. J.</source><year>2024</year><volume>490</volume><fpage>151728</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2024.151728</pub-id></element-citation></ref><ref id="B68-pharmaceutics-17-00225"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>L.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>Q.</given-names></name>
<name><surname>Luo</surname><given-names>G.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Zhong</surname><given-names>G.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Cheng</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Multifunctional 3D-printed scaffolds eradiate orthotopic osteosarcoma and promote osteogenesis via microwave thermo-chemotherapy combined with immunotherapy</article-title><source>Biomaterials</source><year>2023</year><volume>301</volume><elocation-id>122236</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2023.122236</pub-id><pub-id pub-id-type="pmid">37506512</pub-id>
</element-citation></ref><ref id="B69-pharmaceutics-17-00225"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Gu</surname><given-names>L.</given-names></name>
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Miao</surname><given-names>Y.</given-names></name>
<name><surname>Cui</surname><given-names>X.</given-names></name>
</person-group><article-title>A novel anti-CD47 protein antibody and toll-like receptor agonist complex detects tumor surface CD-47 changes in early stage lung cancer by in vivo imaging</article-title><source>Int. J. Biol. Macromol.</source><year>2024</year><volume>274</volume><elocation-id>133322</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.133322</pub-id><pub-id pub-id-type="pmid">38908646</pub-id>
</element-citation></ref><ref id="B70-pharmaceutics-17-00225"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loveless</surname><given-names>R.</given-names></name>
<name><surname>Bloomquist</surname><given-names>R.</given-names></name>
<name><surname>Teng</surname><given-names>Y.</given-names></name>
</person-group><article-title>Pyroptosis at the forefront of anticancer immunity</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2021</year><volume>40</volume><fpage>264</fpage><pub-id pub-id-type="doi">10.1186/s13046-021-02065-8</pub-id><pub-id pub-id-type="pmid">34429144</pub-id>
</element-citation></ref><ref id="B71-pharmaceutics-17-00225"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Min</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
</person-group><article-title>Copper homeostasis and cuproptosis in health and disease</article-title><source>Signal Transduct. Target. Ther.</source><year>2022</year><volume>7</volume><fpage>378</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-01229-y</pub-id><pub-id pub-id-type="pmid">36414625</pub-id>
</element-citation></ref><ref id="B72-pharmaceutics-17-00225"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Deng</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Zhu</surname><given-names>B.</given-names></name>
<name><surname>Bai</surname><given-names>B.</given-names></name>
<name><surname>Mao</surname><given-names>Y.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Yi</surname><given-names>Y.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>PEGylated elesclomol@Cu(II)-based metal&#x02013;organic framework with effective nanozyme performance and cuproptosis induction efficacy for enhanced PD-L1-based immunotherapy</article-title><source>Mater. Today Bio</source><year>2024</year><volume>29</volume><elocation-id>101317</elocation-id><pub-id pub-id-type="doi">10.1016/j.mtbio.2024.101317</pub-id></element-citation></ref><ref id="B73-pharmaceutics-17-00225"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thews</surname><given-names>O.</given-names></name>
<name><surname>Riemann</surname><given-names>A.</given-names></name>
</person-group><article-title>Tumor pH and metastasis: A malignant process beyond hypoxia</article-title><source>Cancer Metastasis Rev.</source><year>2019</year><volume>38</volume><fpage>113</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1007/s10555-018-09777-y</pub-id><pub-id pub-id-type="pmid">30607627</pub-id>
</element-citation></ref><ref id="B74-pharmaceutics-17-00225"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zong</surname><given-names>Z.</given-names></name>
<name><surname>Xie</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>B.</given-names></name>
<name><surname>Zhou</surname><given-names>F.</given-names></name>
</person-group><article-title>Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates P53 and contributes to tumorigenesis</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>2375</fpage><lpage>2392</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2024.04.002</pub-id><pub-id pub-id-type="pmid">38653238</pub-id>
</element-citation></ref><ref id="B75-pharmaceutics-17-00225"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Zhai</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Yin</surname><given-names>H.</given-names></name>
<name><surname>Gao</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Jin</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Metabolic regulation of homologous recombination repair by MRE11 lactylation</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>294</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.11.022</pub-id><pub-id pub-id-type="pmid">38128537</pub-id>
</element-citation></ref><ref id="B76-pharmaceutics-17-00225"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Cao</surname><given-names>Y.</given-names></name>
<name><surname>Ding</surname><given-names>S.</given-names></name>
<name><surname>Zeng</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Cao</surname><given-names>M.</given-names></name>
<name><surname>Duan</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Bian</surname><given-names>X.-W.</given-names></name>
<etal/>
</person-group><article-title>A lactate-depleting metal organic framework-based nanocatalyst reinforces intratumoral T cell response to boost anti-PD1 immunotherapy</article-title><source>J. Colloid Interface Sci.</source><year>2024</year><volume>660</volume><fpage>869</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/j.jcis.2024.01.129</pub-id><pub-id pub-id-type="pmid">38277843</pub-id>
</element-citation></ref><ref id="B77-pharmaceutics-17-00225"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Dai</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Xin</surname><given-names>C.</given-names></name>
<name><surname>An</surname><given-names>Q.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Tian</surname><given-names>L.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
</person-group><article-title>Metal organic frameworks based intelligent nanoadjuvants for boosting tumor immunotherapy through enhanced ICD and lactic acid regulation</article-title><source>Chem. Eng. J.</source><year>2024</year><volume>479</volume><fpage>147464</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2023.147464</pub-id></element-citation></ref><ref id="B78-pharmaceutics-17-00225"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>B.</given-names></name>
<name><surname>Liao</surname><given-names>K.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Wen</surname><given-names>T.</given-names></name>
<name><surname>Quan</surname><given-names>G.</given-names></name>
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
</person-group><article-title>Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy</article-title><source>Biomaterials</source><year>2021</year><volume>277</volume><elocation-id>121110</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121110</pub-id><pub-id pub-id-type="pmid">34482088</pub-id>
</element-citation></ref><ref id="B79-pharmaceutics-17-00225"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>Y.</given-names></name>
<name><surname>Xiao</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
</person-group><article-title>Engineering nanomedicine for glutathione depletion-augmented cancer therapy</article-title><source>Chem. Soc. Rev.</source><year>2021</year><volume>50</volume><fpage>6013</fpage><lpage>6041</lpage><pub-id pub-id-type="doi">10.1039/D0CS00718H</pub-id><pub-id pub-id-type="pmid">34027953</pub-id>
</element-citation></ref><ref id="B80-pharmaceutics-17-00225"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lequeux</surname><given-names>A.</given-names></name>
<name><surname>Noman</surname><given-names>M.Z.</given-names></name>
<name><surname>Xiao</surname><given-names>M.</given-names></name>
<name><surname>Van Moer</surname><given-names>K.</given-names></name>
<name><surname>Hasmim</surname><given-names>M.</given-names></name>
<name><surname>Benoit</surname><given-names>A.</given-names></name>
<name><surname>Bosseler</surname><given-names>M.</given-names></name>
<name><surname>Viry</surname><given-names>E.</given-names></name>
<name><surname>Arakelian</surname><given-names>T.</given-names></name>
<name><surname>Berchem</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy</article-title><source>Oncogene</source><year>2021</year><volume>40</volume><fpage>4725</fpage><lpage>4735</lpage><pub-id pub-id-type="doi">10.1038/s41388-021-01846-x</pub-id><pub-id pub-id-type="pmid">34155342</pub-id>
</element-citation></ref><ref id="B81-pharmaceutics-17-00225"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Najafi</surname><given-names>A.</given-names></name>
<name><surname>Keykhaee</surname><given-names>M.</given-names></name>
<name><surname>Khorramdelazad</surname><given-names>H.</given-names></name>
<name><surname>Karimi</surname><given-names>M.Y.</given-names></name>
<name><surname>Nejatbakhsh Samimi</surname><given-names>L.</given-names></name>
<name><surname>Aghamohamadi</surname><given-names>N.</given-names></name>
<name><surname>Karimi</surname><given-names>M.</given-names></name>
<name><surname>Falak</surname><given-names>R.</given-names></name>
<name><surname>Khoobi</surname><given-names>M.</given-names></name>
</person-group><article-title>Catalase application in cancer therapy: Simultaneous focusing on hypoxia attenuation and macrophage reprogramming</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>153</volume><elocation-id>113483</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113483</pub-id><pub-id pub-id-type="pmid">36076502</pub-id>
</element-citation></ref><ref id="B82-pharmaceutics-17-00225"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Q.-X.</given-names></name>
<name><surname>Liang</surname><given-names>J.-L.</given-names></name>
<name><surname>Chen</surname><given-names>Q.-W.</given-names></name>
<name><surname>Jin</surname><given-names>X.-K.</given-names></name>
<name><surname>Niu</surname><given-names>M.-T.</given-names></name>
<name><surname>Dong</surname><given-names>C.-Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.-Z.</given-names></name>
</person-group><article-title>Metal-organic framework nanoagent induces cuproptosis for effective immunotherapy of malignant glioblastoma</article-title><source>Nano Today</source><year>2023</year><volume>51</volume><fpage>101911</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2023.101911</pub-id></element-citation></ref><ref id="B83-pharmaceutics-17-00225"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Xiao</surname><given-names>Z.</given-names></name>
<name><surname>Lin</surname><given-names>M.</given-names></name>
<name><surname>Zhong</surname><given-names>H.</given-names></name>
<name><surname>Shuai</surname><given-names>X.</given-names></name>
</person-group><article-title>Metal-organic framework nanoparticles hitchhiking on T cells for protein delivery to boost anticancer immunotherapy</article-title><source>Nano Today</source><year>2024</year><volume>54</volume><fpage>102102</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2023.102102</pub-id></element-citation></ref><ref id="B84-pharmaceutics-17-00225"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
<name><surname>Xu</surname><given-names>R.</given-names></name>
<name><surname>Wei</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zuo</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Deng</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>N.</given-names></name>
<name><surname>Shen</surname><given-names>Q.</given-names></name>
</person-group><article-title>Smart biomimetic metal organic rrameworks based on ROS-ferroptosis-glycolysis regulation for enhanced tumor chemo-immunotherapy</article-title><source>J. Control. Release</source><year>2021</year><volume>334</volume><fpage>21</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.04.013</pub-id><pub-id pub-id-type="pmid">33872626</pub-id>
</element-citation></ref><ref id="B85-pharmaceutics-17-00225"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>T.C.</given-names></name>
<name><surname>Langer</surname><given-names>R.</given-names></name>
<name><surname>Wood</surname><given-names>M.J.A.</given-names></name>
</person-group><article-title>Wood. Advances in oligonucleotide drug delivery</article-title><source>Nat. Rev. Drug Discov.</source><year>2020</year><volume>19</volume><fpage>673</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1038/s41573-020-0075-7</pub-id><pub-id pub-id-type="pmid">32782413</pub-id>
</element-citation></ref><ref id="B86-pharmaceutics-17-00225"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Lei</surname><given-names>J.</given-names></name>
</person-group><article-title>Multifunctional metal&#x02013;organic framework heterostructures for enhanced cancer therapy</article-title><source>Chem. Soc. Rev.</source><year>2021</year><volume>50</volume><fpage>1188</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1039/D0CS00178C</pub-id><pub-id pub-id-type="pmid">33283806</pub-id>
</element-citation></ref><ref id="B87-pharmaceutics-17-00225"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alshaer</surname><given-names>W.</given-names></name>
<name><surname>Zureigat</surname><given-names>H.</given-names></name>
<name><surname>Al Karaki</surname><given-names>A.</given-names></name>
<name><surname>Al-Kadash</surname><given-names>A.</given-names></name>
<name><surname>Gharaibeh</surname><given-names>L.</given-names></name>
<name><surname>Hatmal</surname><given-names>M.M.M.</given-names></name>
<name><surname>Aljabali</surname><given-names>A.A.A.</given-names></name>
<name><surname>Awidi</surname><given-names>A.</given-names></name>
</person-group><article-title>siRNA: Mechanism of action, challenges, and therapeutic approaches</article-title><source>Eur. J. Pharmacol.</source><year>2021</year><volume>905</volume><fpage>174178</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174178</pub-id><pub-id pub-id-type="pmid">34044011</pub-id>
</element-citation></ref><ref id="B88-pharmaceutics-17-00225"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>N.</given-names></name>
<name><surname>Lei</surname><given-names>Q.</given-names></name>
<name><surname>Wu</surname><given-names>M.</given-names></name>
<name><surname>Gao</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Lv</surname><given-names>X.</given-names></name>
<name><surname>Wei</surname><given-names>R.</given-names></name>
<name><surname>Yan</surname><given-names>F.</given-names></name>
<name><surname>Cai</surname><given-names>L.</given-names></name>
</person-group><article-title>Metal-organic framework-mediated siRNA delivery and sonodynamic therapy for precisely triggering ferroptosis and augmenting ICD in osteosarcoma</article-title><source>Mater. Today Bio</source><year>2024</year><volume>26</volume><elocation-id>101053</elocation-id><pub-id pub-id-type="doi">10.1016/j.mtbio.2024.101053</pub-id></element-citation></ref><ref id="B89-pharmaceutics-17-00225"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>K.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Cao</surname><given-names>T.</given-names></name>
<name><surname>Yuan</surname><given-names>S.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Bai</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Nano-enabled regulation of DNA damage in tumor cells to enhance neoantigen-based pancreatic cancer immunotherapy</article-title><source>Biomaterials</source><year>2024</year><volume>311</volume><elocation-id>122710</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2024.122710</pub-id><pub-id pub-id-type="pmid">39053036</pub-id>
</element-citation></ref><ref id="B90-pharmaceutics-17-00225"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alsharafi</surname><given-names>W.A.</given-names></name>
<name><surname>Xiao</surname><given-names>B.</given-names></name>
<name><surname>Abuhamed</surname><given-names>M.M.</given-names></name>
<name><surname>Luo</surname><given-names>Z.</given-names></name>
</person-group><article-title>miRNAs: Biological and clinical determinants in epilepsy</article-title><source>Front. Mol. Neurosci.</source><year>2015</year><volume>8</volume><elocation-id>59</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2015.00059</pub-id><pub-id pub-id-type="pmid">26528124</pub-id>
</element-citation></ref><ref id="B91-pharmaceutics-17-00225"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>C.</given-names></name>
<name><surname>He</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Kang</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>W.</given-names></name>
<name><surname>Nian</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Weng</surname><given-names>H.</given-names></name>
</person-group><article-title>Targeted miR-34a delivery with PD1 displayed bacterial outer membrane vesicles-coated zeolitic imidazolate framework nanoparticles for enhanced tumor therapy</article-title><source>Int. J. Biol. Macromol.</source><year>2023</year><volume>247</volume><elocation-id>125692</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2023.125692</pub-id><pub-id pub-id-type="pmid">37414322</pub-id>
</element-citation></ref><ref id="B92-pharmaceutics-17-00225"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>D.</given-names></name>
<name><surname>Moya</surname><given-names>S.</given-names></name>
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Qiu</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Pan</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Bispecific T-cell engager (BiTE) immunotherapy of ovarian cancer based on MIL-88A MOF/MC gene delivery system</article-title><source>Appl. Mater. Today</source><year>2020</year><volume>20</volume><fpage>100701</fpage><pub-id pub-id-type="doi">10.1016/j.apmt.2020.100701</pub-id></element-citation></ref><ref id="B93-pharmaceutics-17-00225"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drew</surname><given-names>L.</given-names></name>
</person-group><article-title>Cancer-vaccine trials give reasons for optimism</article-title><source>Nature</source><year>2024</year><volume>627</volume><fpage>S33</fpage><pub-id pub-id-type="doi">10.1038/d41586-024-00840-z</pub-id><pub-id pub-id-type="pmid">38538945</pub-id>
</element-citation></ref><ref id="B94-pharmaceutics-17-00225"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jhunjhunwala</surname><given-names>S.</given-names></name>
<name><surname>Hammer</surname><given-names>C.</given-names></name>
<name><surname>Delamarre</surname><given-names>L.</given-names></name>
</person-group><article-title>Antigen presentation in cancer: Insights into tumour immunogenicity and immune evasion</article-title><source>Nat. Rev. Cancer</source><year>2021</year><volume>21</volume><fpage>298</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00339-z</pub-id><pub-id pub-id-type="pmid">33750922</pub-id>
</element-citation></ref><ref id="B95-pharmaceutics-17-00225"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhan</surname><given-names>G.</given-names></name>
<name><surname>Xu</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Wei</surname><given-names>Z.</given-names></name>
<name><surname>Yong</surname><given-names>T.</given-names></name>
<name><surname>Bie</surname><given-names>N.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Gan</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Biomimetic sonodynamic therapy-nanovaccine integration platform potentiates anti-PD-1 therapy in hypoxic tumors</article-title><source>Nano Today</source><year>2021</year><volume>38</volume><fpage>101195</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2021.101195</pub-id></element-citation></ref><ref id="B96-pharmaceutics-17-00225"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Tan</surname><given-names>L.</given-names></name>
<name><surname>Zheng</surname><given-names>T.</given-names></name>
<name><surname>Hou</surname><given-names>Y.</given-names></name>
<name><surname>Hong</surname><given-names>X.</given-names></name>
<name><surname>Du</surname><given-names>G.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
</person-group><article-title>An aluminum adjuvant-integrated nano-MOF as antigen delivery system to induce strong humoral and cellular immune responses</article-title><source>J. Control. Release</source><year>2019</year><volume>300</volume><fpage>81</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.02.035</pub-id><pub-id pub-id-type="pmid">30826373</pub-id>
</element-citation></ref><ref id="B97-pharmaceutics-17-00225"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Harnessing whole tumor cells for tumor immunotherapy</article-title><source>Innov. Mater.</source><year>2023</year><volume>1</volume><fpage>100018</fpage><pub-id pub-id-type="doi">10.59717/j.xinn-mater.2023.100018</pub-id></element-citation></ref><ref id="B98-pharmaceutics-17-00225"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zeng</surname><given-names>L.</given-names></name>
<name><surname>Yin</surname><given-names>W.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Zou</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>Z.</given-names></name>
<name><surname>Dai</surname><given-names>Z.</given-names></name>
</person-group><article-title>Cell-Selective encapsulation within metal&#x02013;organic framework shells via precursor-functionalized aptamer identification for whole-cell cancer vaccine</article-title><source>Small Methods</source><year>2022</year><volume>6</volume><fpage>2101391</fpage><pub-id pub-id-type="doi">10.1002/smtd.202101391</pub-id><pub-id pub-id-type="pmid">35107224</pub-id>
</element-citation></ref><ref id="B99-pharmaceutics-17-00225"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Cao</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Song</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
</person-group><article-title>Ferroptosis-induced immunomodulation with biometabolic MOF@COF nanovaccine for self-boosting anti-tumor immunotherapy</article-title><source>Chem. Eng. J.</source><year>2024</year><volume>493</volume><fpage>152675</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2024.152675</pub-id></element-citation></ref><ref id="B100-pharmaceutics-17-00225"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Tan</surname><given-names>L.</given-names></name>
<name><surname>Dai</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>M.-D.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Manganese-based microcrystals equipped with Ythdf1-targeted biomimetic nanovaccines for reinforced dendritic cell spatiotemporal orchestration</article-title><source>Nano Today</source><year>2024</year><volume>54</volume><fpage>102112</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2023.102112</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00225-f001"><label>Figure 1</label><caption><p>The cancer-immunity cycle. Adapted with permission from ref [<xref rid="B8-pharmaceutics-17-00225" ref-type="bibr">8</xref>]. Copyright 2013 Elsevier.</p></caption><graphic xlink:href="pharmaceutics-17-00225-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00225-f002"><label>Figure 2</label><caption><p>Metal&#x02013;organic frameworks as carriers for cancer immunotherapy.</p></caption><graphic xlink:href="pharmaceutics-17-00225-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00225-f003"><label>Figure 3</label><caption><p>(<bold>a</bold>) The classification and of MOFs. (<bold>b</bold>) The drug-loading methods of MOFs.</p></caption><graphic xlink:href="pharmaceutics-17-00225-g003" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00225-t001"><object-id pub-id-type="pii">pharmaceutics-17-00225-t001_Table 1</object-id><label>Table 1</label><caption><p>MOF-based drug delivery systems for tumor immunotherapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MOF Type</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Metal Type</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MOF Name</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Linker</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cargo</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coating</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune Activation</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="32" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Mono-metal MOFs</td><td rowspan="8" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Fe</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COS@MOF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-aminoterephthalic acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan oligosaccharide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ferroptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-pharmaceutics-17-00225" ref-type="bibr">34</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lip-MOF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tri-mellitic-anhydride</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyroptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-pharmaceutics-17-00225" ref-type="bibr">35</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p-LDM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,4-benzenedicarboxylicacid (H<sub>2</sub>BDC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin (DOX)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOPC<break/>DSPE-PEG2000<break/>Pep-DSPE-PEG2000</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ferroptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-pharmaceutics-17-00225" ref-type="bibr">43</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPI549@MOF/CpG NPs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tannic acid (TA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPI549<break/>CpG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR9 pathway activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-pharmaceutics-17-00225" ref-type="bibr">55</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLSLF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dithiodiglycolic acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lactate oxidase, siMCT4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Folate-liposomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GSH depletion,&#x000b7;OH generation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-pharmaceutics-17-00225" ref-type="bibr">77</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fe(SS)DG MOF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dithiodiglycolic acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOX<break/>glucose oxidase (Gox)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell membrane</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ROS-ferroptosis-glycolysis regulation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-pharmaceutics-17-00225" ref-type="bibr">84</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOF/MC.BiTE</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trimesic acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minicircle DNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T cell activation, BiTE expression</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-pharmaceutics-17-00225" ref-type="bibr">94</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NMCAH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NH<sub>2</sub>-BDC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arachidonic acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzaldehyde<break/>Phenylenediamine<break/>hyaluronic acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ferroptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-pharmaceutics-17-00225" ref-type="bibr">99</xref>]</td></tr><tr><td rowspan="12" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Zn</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sup>F127</sup>ZIF-8<sub>CCCP</sub> NPs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-methylimidazole (2-MIM)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carbonyl cyano-m-chlorophenone (CCCP)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F127</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyroptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmaceutics-17-00225" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PMDC NPs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terephthalic acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dihydroartemisinin (DHA), CORM-401</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pHCT74</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis, ferroptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-pharmaceutics-17-00225" ref-type="bibr">45</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(M + H)@ZIF/HA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydralazine (HYD), mitoxantrone (MIT)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hyaluronic acid (HA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyroptosis, MGO reduction</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-pharmaceutics-17-00225" ref-type="bibr">47</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MTX-PEG@TPL@ZIF-8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Triptolide (TPL)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COOH-PEG2000-MTX</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cleaved Caspase-9/3 pathway activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-pharmaceutics-17-00225" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IDN@MC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decitabine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR-MC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyroptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-pharmaceutics-17-00225" ref-type="bibr">50</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CZFNP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NH<sub>2</sub>-PEG-FA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STING and PEG-2 pathway activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-pharmaceutics-17-00225" ref-type="bibr">61</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZDI</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOX<break/>IDO inhibitors</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3D-printed scaffolds</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICD, ICB</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-pharmaceutics-17-00225" ref-type="bibr">68</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX@ZIF-8@MPN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lactate oxidase</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fe-Metallic polyphenol network</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis, ICD, Vascular normalization</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B76-pharmaceutics-17-00225" ref-type="bibr">76</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C&#x00026;H@MOF/PL</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Catalase, hemoglobin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apd-1, DSPC, NDPPA-PEG-CDM, cholesterol</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypoxia relief</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-pharmaceutics-17-00225" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOF<sub>DOX@siATR</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOX<break/>siATR</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siRNA silence<break/>ICD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-pharmaceutics-17-00225" ref-type="bibr">89</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OMV@ZIF-8@pre-miRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-miRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacterial outer membrane vesicles expressing PD-1 (OMV-PD-1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA degradation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-pharmaceutics-17-00225" ref-type="bibr">92</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apt-Cell@ZIF-8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer cell</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRT explosion, tumor antigen presentation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-pharmaceutics-17-00225" ref-type="bibr">98</xref>]</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Cu</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S@Cu-MOF/PPI</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bis(trichloromethyl) carbonate (BTC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyphyllin I (PPI)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cuproptosis, STING pathway, apoptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-pharmaceutics-17-00225" ref-type="bibr">58</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu(II)-MOF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BTC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elesclomol (ES)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyethylene glycol, (PEG)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cuproptosis<break/>ICD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-pharmaceutics-17-00225" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCMD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,3,5-Benzenetricarboxylic acid (H<sub>3</sub>BTC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Catalase, buthionine-sul foximine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dodecyl-beta-D-maltoside</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICD, cuproptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-pharmaceutics-17-00225" ref-type="bibr">82</xref>]</td></tr><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Mn</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mn-MOF@PEG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,5-dihydroxyterephthalic acid (H<sub>4</sub>DOBDC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dicyclohexyl carbodiimide (DCC),<break/>PEG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DCs muturation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-pharmaceutics-17-00225" ref-type="bibr">36</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOX@Zr-MOF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5,10,15,20-tetrakis(4-carbonxyphenyl) porphyrin (TCPP)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOX</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPE-PEG2000-NH<sub>2</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICD, Caspase-dependent pathway activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-pharmaceutics-17-00225" ref-type="bibr">49</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BT-isMOFs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terephthalic acid (H<sub>2</sub>BDC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zoledronic acid (ZOL)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR9 pathway activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-pharmaceutics-17-00225" ref-type="bibr">55</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOF-CpG-DMXAA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fumaric acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5, 6-dimethylflavono-4-acetic acid (DMXAA), CpG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Starvation therapy, <break/>TLR9 and STING pathway activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-pharmaceutics-17-00225" ref-type="bibr">59</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cMn-MOF@CM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzoic acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG, bovine serum albumin (BSA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B16-OVA membrane</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen presentation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-pharmaceutics-17-00225" ref-type="bibr">95</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ti</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PMPPO</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NH<sub>2</sub>-H<sub>2</sub>BDC, BA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pt<break/>O<sub>2</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICD, apoptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-pharmaceutics-17-00225" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hf</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DBP-Hf MOFs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H<sub>2</sub>DBP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,3 cyclic guanosine monophosphate&#x02014;adenosine monophosphate (GA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAS-STING pathway activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-pharmaceutics-17-00225" ref-type="bibr">57</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gd/MPC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fumaric acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aPD-1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-Tetradecanol<break/>SCC7-cell membrance</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICB, apoptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-pharmaceutics-17-00225" ref-type="bibr">65</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Al</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICG-R848@Al-MOFs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NH<sub>2</sub>-BDC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;-CD47, ICG, R848</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICB, TLR pathway activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-pharmaceutics-17-00225" ref-type="bibr">69</xref>]</td></tr><tr><td rowspan="8" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Binary-metal MOFs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gd<break/>Zn</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gd-MOF-5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H<sub>2</sub>BDC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TMEM 16F Deactivation<break/>ICD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICD, TMEM 16F deactivation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmaceutics-17-00225" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mn<break/>Fe</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MMCH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oleic acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisplatin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ferroptosis, ICD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-pharmaceutics-17-00225" ref-type="bibr">44</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fe<break/>Mn</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FeMn@R@H</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-aminoterephthalic acid, citric acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R848</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyroptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B54-pharmaceutics-17-00225" ref-type="bibr">54</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fe<break/>Gd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LEN@Gd/FeMOF-PEG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trimesic acid<break/>Fumaric acid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Levatinib</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mpeg-SH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-pharmaceutics-17-00225" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<break/>Zn</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CPD@M-TDN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DA, DOX</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M-TDN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICD, GSH depletion</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-pharmaceutics-17-00225" ref-type="bibr">67</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fe<break/>Zr</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mFeP@si</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H<sub>2</sub>TCPP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siGPX4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OS cell membrane</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ferroptosis, GPX4 silence</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-pharmaceutics-17-00225" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zn<break/>Al</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZANPs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovalbumin (OVA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen presentation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-pharmaceutics-17-00225" ref-type="bibr">96</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mn<break/>Zr</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mn/Zr-MOF-shY1-CM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TCPP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">shY1-plasmid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell membrane</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STING pathway activation, <break/>Ythdf 1 silence</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-pharmaceutics-17-00225" ref-type="bibr">100</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tri-metal MOFs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<break/>Au<break/>Zn</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACS-Z-P NPs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-MIM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Purpurin 18</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Purpurin 18</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyroptosis, ICD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-pharmaceutics-17-00225" ref-type="bibr">39</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>